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Preface 
 
I have always wanted to be a neurosurgeon but the decision to pursue a career in 
science came later in my life. I did my residency in Neurosurgery at Hospital de Santa Maria 
from 2004 to 2010 and I devoted the last years of training to Pediatric Neurosurgery. My 
interest in brain tumor research arose from my patients, particularly from those difficult cases 
where, despite a successful operation, the tumor recurred thus emphasizing the importance of 
understanding the tumor biology for patient management.  
Having this in mind, and with the invaluable support of Professor João Lobo Antunes, 
I applied to the Programme for Advanced Medical Education in 2009, a PhD program for 
medical doctors, sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, 
Ministério da Saúde e Fundação para a Ciência e Tecnologia. The initial six months of the 
program included classes and seminars on various topics, from basic science to translational 
research and epidemiology. The goal of this educational period was to provide the students 
with solid scientific basis to develop research projects oriented for specific clinical questions.  
When I joined the program I had the naïve assumption that I couldn’t stay away from 
my natural environment, the operating room without loosing the skills acquired during six 
years of intense surgical training. The switch from a purely clinical thinking to an integrated 
clinical and scientific thinking was hard but it became a milestone in my medical career. 
Having a clear clinical question in mind I have decided to develop my research project in a 
renowned international brain tumor research centre, The Arthur and Sonia Labatt Brain 
Tumour Research Centre, at the Hospital for Sick Children in Toronto, Canada.  
The choice to move to Toronto was simple. During my residency I had visited for a 
period the Divison of Neurosurgery at the Hospital for Sick Children in Toronto and I met Dr. 
James Rutka, pediatric neurosurgeon, senior scientist and Director of The Arthur and Sonia 
Labatt Brain Tumour Research Centre. Knowing my interest in brain tumor research, he 
invited me to visit the Centre, showed me the facilities, explained the main research areas and 
ongoing projects, and introduced me to some of the researchers. When, two years later, I had 
to choose a research institute to develop my project, I had no doubt that the Labatt Brain 
Tumour Research Centre was the right place and, therefore, I was extremely grateful for 
being accepted in Dr. Rutka’s laboratory.  
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 I have decided to focus on medulloblastoma, the most common malignant brain 
tumor in the pediatric population. I was puzzled with the heterogeneous clinical outcome of 
patients with medulloblastoma treated with standard protocols and I felt that better therapeutic 
options were urgently needed. The “boom” of genomic data emerging from the study of large 
cohorts of medulloblastoma samples had recently started. I was fortunate to work at the 
Labatt Brain Tumour Research Centre when major discoveries on medulloblastoma took 
place and also to give my contribution to some of those projects. The results from my own 
research project opened new avenues for targeted therapies and I hope they can translate into 
clinical trials for children with medulloblastoma in a near future. 
My overall experience in Toronto exceeded my best expectations. During my 
“research residency”, as I like to refer to my training in the laboratory, I have learned a wide 
variety of techniques, I became familiar with the latest technologies in the field and, most 
importantly, I met extraordinary people from around the globe and created a network of 
collaborations that will certainly be of great value for my future projects. The exceptional 
environment at the Labatt Brain Tumour Research Centre have been truly inspiring and, now 
that I am back to my home institution, I hope to pursue a career as a clinician-scientist to 
better help my patients both in the operating room and in the laboratory.     
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Abstract 
Medulloblastoma is the most common malignant brain tumor in childhood. The 
standard of care to treat patients with medulloblastoma includes surgical resection, 
craniospinal irradiaton (in children older than 3 years of age) and high dose chemotherapy. 
Overall survival rates for patients submitted to conventional treatment protocols have reached 
70-80% but the majority of survivors suffer from severe long-term side effects, including 
developmental, cognitive, neurological and neuroendocrine deficits. 
For many years medulloblastoma was considered a single entity, a small, round blue-
cell tumor on histology, originating in the cerebellum. Recently, integrative genomic studies 
have identified at least four distinct molecular subgroups – WNT, sonic hedgehog (SHH), 
Group 3 and Group 4 – which display disparate transcriptional profiles, genetic abnormalities, 
patient demographics and clinical outcome. Patients with WNT medulloblastomas have a 
very good outcome. Patients with SHH and Group 4 tumors have an intermediate prognosis. 
Group 3 medulloblastomas are characterized by frequent amplifications or aberrant 
expression of the oncogene MYC, a high percentage of metastasis at diagnosis and a very poor 
prognosis despite aggressive therapy. Although disseminated disease at diagnosis is a known 
factor of poor survival, the mechanisms of dissemination are not fully understood and 
metastatic lesions are highly genetically divergent from their matched primary tumor. 
Therefore, we asked whether we could use genomics to discover novel and less toxic small 
molecule inhibitors to target medulloblastoma in a subgroup-specific manner. 
To answer our research question we used two approaches: 1) targeting the hepatocyte 
growth factor (HGF)/cMET pathway, known to be important in medulloblastoma 
pathogenesis, with the cMET inhibitor, foretinib and 2) performing a gene expression-based 
in silico drug screen to identify small molecule inhibitors with selective antitumor effect in 
Group 3 medulloblastomas. 
 
Aberrant signaling through the (HGF)/cMET pathway is involved in tumor 
progression and metastasis in several human cancers. cMET is a transmembrane receptor 
which becomes activated through phosphorylation of tyrosine residues upon binding of its 
ligand HGF. The recruiment of cytoplasmic effector proteins upon cMET activation triggers 
multiple downstream effector pathways including mitogen activated protein kinase (MAPK) 
and phosphoinositide 3-kinase (PI3K). In medulloblastoma, cMET activation has been 
associated with tumor growth and invasion. To determine the subgroup-specific role of cMET 
  24 
in medulloblastoma, we analyzed the mRNA expression of three large non-overlapping 
cohorts of patients with primary medulloblastomas (discovery cohort from Boston, n = 199; 
validation cohort 1, a multicentre cohort obtained from Heidelberg, n = 439; validation cohort 
2, a multicentre cohort obtained from the Medulloblastoma Advanced Genomics International 
Consortium - MAGIC, n = 285) and demonstrated that cMET is a marker of SHH 
medulloblastoma. Immunohistochemical analysis of activated cMET (phosphorylated cMET) 
in another independent patient cohort (n = 385) validated these findings and revealed that 
cMET activation correlates with increased tumor relapse and a poor survival in pediatric 
patients with SHH medulloblastomas, thus defining a subset of patients that may benefit from 
cMET targeted therapy.  
We selected foretinib, an FDA approved multikinase inhibitor with high affinity to the 
cMET receptor, to evaluate the effect of cMET targeting in SHH medulloblastoma. Foretinib 
suppressed cMET activation, decreased proliferation and induced apoptosis, both in 
medulloblastoma cell lines and in SHH medulloblastoma flank xenografts. Importantly, we 
characterized the pharmacokinetics of foretinib and demonstrated that it penetrates the blood-
brain barrier and is well tolerated through intrathecal administration. Treatment of mouse 
intracranial xenografts and of an aggressive transgenic mouse model of metastatic SHH 
medulloblastoma (Patched+/- mouse with the Sleeping Beauty transposon system) with 
foretinib reduced primary medulloblastoma growth and invasion, decreased the incidence of 
metastases by 36% and increased survival by 45%.  
 
 To investigate potential novel small molecules to target Group 3 medulloblastomas we 
used a bioinformatic platform called the Connectivity Map (C-MAP). The C-MAP contains a 
collection of gene expression profiles from several human cell lines treated with a large 
number of compounds already FDA approved. Comparative analysis between the oncogenic 
gene signature of interest and the C-MAP database may highlight patterns of gene expression 
change and identify small molecules with potential predicted activity within a given cancer. 
We queried the C-MAP using the subgroup-specific gene expression signatures of the four 
medulloblastoma subgroups. Piperlongumine, a natural product extracted from the fruit of the 
Piper longum, was the top candidate drug for non-WNT tumors. We then selected compounds 
predicted to have specific antitumor activity for Group 3 medulloblastomas and the cyclin-
dependent kinase (CDK) inhibitor alsterpaullone ranked number one. To validate our findings 
we used two established Group 3 medulloblastoma cell lines (D425 and D458) and a 
medulloblastoma stem cell line derived from a patient with a Group 3 tumor (M441). The C-
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MAP predicted drugs were able to decrease cell proliferation in vitro and to reduce tumor 
growth and increase survival in Group 3 medulloblastoma mouse xenografts. Alsterpaullone 
showed the highest efficacy both in vitro and in vivo in the patient derived medulloblastoma 
stem cell line. Interestingly, the chemical genomic profiling of Group 3 medulloblastoma 
cells treated with alsterpaullone confirmed inhibition of cell cycle-related genes and showed 
down-regulation of MYC, the hallmark oncogene of Group 3 tumors.  
 
 We used a gene expression-based approach to identify molecular targeted therapy to 
treat medulloblastoma. Our results demonstrate the preclinical efficacy of two small molecule 
inhibitors: foretinib in metastatic SHH medulloblastomas and alterpaullone in Group 3 
tumors. Given the dismal outcome and lack of options for these patients, the results from our 
studies provide strong rationale for advancing both compounds as targeted agents into clinical 
trials for patients with these highly aggressive subgroups of medulloblastoma. 
 
 
 
Keywords: medulloblastoma subgroups, genomics, HGF/cMET pathway, foretinib, 
alsterpaullone  
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Resumo 
O meduloblastoma é o tumor cerebral maligno mais comum na população pediátrica. 
O tratamento convencional dos doentes com meduloblastoma inclui resseção cirúrgica 
máxima, radioterapia do crânio e do neuroeixo (em crianças com idade superior a 3 anos) e 
quimioterapia de alta dose. A sobrevida global em doentes submetidos a protocolos de 
tratamento convencional atinge os 70-80% mas a maioria dos sobreviventes apresenta 
sequelas graves dos tratamentos incluindo problemas no desenvolvimento, defeitos 
cognitivos, neurológicos e neuroendócrinos.  
Durante muito anos o meduloblastoma foi considerado uma entidade única, um tumor 
de pequenas células azuis na observação histológica, oriundo do cerebelo. Recentemente, 
estudos de genómica integrada identificaram pelo menos quatro subgrupos moleculares de 
meduloblastoma – WNT, sonic hedgehog (SHH), Grupo 3 e Grupo 4 – que apresentam 
características distintas no que diz respeito ao perfil transcriptómico, anomalias genéticas, 
dados demográficos e sobrevida. Doentes com meduloblastomas do tipo WNT têm muito 
bom prognóstico. Doentes com tumores do tipo SHH e Grupo 4 têm um prognóstico 
intermédio. Os meduloblastomas do Grupo 3 são caracterizados por amplificações frequentes 
ou expressão aberrante do oncogene MYC, uma elevada incidência de metástases na altura do 
diagnóstico e um mau prognóstico apesar de terapias agressivas. Embora a presença de 
doença disseminada na altura do diagnóstico seja um factor conhecido de baixa sobrevida, os 
mecanismos de disseminação são pouco conhecidos e as lesões metastáticas são 
geneticamente divergentes do seu tumor primário. Assim, questionámos se seria possível usar 
a genómica na descoberta de pequenas moléculas inibidoras dirigidas aos subgrupos 
moleculares de meduloblastoma. 
Para responder à nossa pergunta utilizámos duas abordagens: 1) uma terapia dirigida à 
via de sinalização do factor de crescimento dos hepatócitos (HGF)/cMET, conhecida pelo seu 
importante papel na patogénese do meduloblastoma, usando um inibidor do receptor cMET, 
foretinib e 2) um rastreio farmacológico in silico com base na expressão genética para 
identificar pequenas moléculas inibidoras com efeito antitumoral selectivo nos 
meduloblastomas do Grupo 3. 
 
 A sinalização aberrante através da via de transdução de sinal (HGF)/cMET está 
envolvida na progressão tumoral e metastização de vários cancros humanos. cMET é um 
receptor transmembranar que é activado através da fosforilação de resíduos de tirosina, após 
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interacção com o seu ligando HGF. O recrutamento de proteinas efectoras citoplasmáticas 
após a activação de cMET desencadeia a activação de múltiplas vias de sinalização incluindo 
MAPK (mitogen activated protein kinase) e PI3K (phosphoinositide 3-kinase). No 
meduloblastoma a activação de cMET tem sido associada a crescimento e invasão tumoral. 
Para determinar a importância de cMET nos diferentes subgrupos de meduloblastoma, 
analizámos a expressão de mRNA em três grupos independentes de doentes com 
meduloblastomas primários (grupo de descoberta de Boston, n = 199; grupo de validação 1, 
grupo multicêntrico obtido de Heidelberg, n = 439; grupo de validação 2, grupo multicêntrico 
obtido do Medulloblastoma Advanced Genomics International Consortium - MAGIC, n = 
285) e demonstrámos que cMET é um marcador do meduloblastoma do tipo SHH. A análise 
imunohistoquímica de cMET activado (ou cMET fosforilado) noutro grupo independente de 
doentes (n = 385) validou estes resultados e revelou que a activação de cMET se correlaciona 
com o aumento de recidivas tumorais e com uma baixa sobrevida em doentes pediátricos com 
meduloblastoma do tipo SHH, definido assim um subgrupo de doentes que pode beneficiar de 
terapêutica dirigida a cMET. 
 Seleccionámos foretinib, um inibidor de múltiplas cinases aprovado pela FDA e com 
elevada afinidade para cMET, para avaliar o efeito da terapia dirigida a cMET no 
meduloblastoma do tipo SHH. Foretinib bloqueou a activação de cMET, reduziu a 
proliferação celular e induziu apoptose, tanto em linhas celulares de meduloblastoma como 
em tumores implantados no flanco de ratinhos. Importa salientar que caracterizámos a 
farmacocinética do foretinib e demonstrámos que este fármaco penetra a barreira hemato-
encefálica e é bem tolerado quando administrado por via intratecal. O tratamento com 
foretinib em ratinhos com meduloblastomas implantados no cerebelo e num modelo de 
ratinho transgénico com uma forma agressiva de meduloblastoma metastizado do tipo SHH 
(ratinho transgénico Patched+/- com sistema de transposão do tipo Sleeping Beauty) reduziu o 
crescimento e invasão em meduloblastomas primários, diminuiu a incidência de metástases 
em 36% e aumentou a sobrevida em 45%. 
 
 Para investigar potenciais novas pequenas moléculas dirigidas aos meduloblastomas do 
Grupo 3, usámos uma plataforma bioinformática chamada Connectivity Map (C-MAP). O C-
MAP contém uma colecção de perfis de expressão génica de múltiplas linhas celulares 
humanas tratadas com um elevado número de compostos aprovados pela FDA. A análise 
comparativa entre assinaturas genéticas oncogénicas de interesse e a base de dados C-MAP 
pode detectar padrões de mudança de expressão génica e identificar pequenas moléculas com 
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potencial actividade num determinado cancro. Assim, questionámos o C-MAP usando as 
assinaturas genéticas específicas dos quatro subgrupos de meduloblastoma. Piperlongumine, 
um produto natural extaído do fruto do Piper longum, foi identificado como o melhor 
candidato para os diferentes subgrupos de meduloblastoma, à excepção do tipo WNT. De 
seguida, seleccionámos compostos com potencial actividade antitumoral específica para os 
meduloblastomas do Grupo 3, tendo um inibidor das CDKs (cyclin-dependent kinases), 
alsperpaullone, sido o melhor classificado. Para validar os nossos resultados usámos duas 
linhas celulares estabelecidas representativas dos meduloblastomas do Grupo 3 (D425 e 
D458) e uma linha celular pluripotente obtida de um doente com um tumor do Grupo 3 
(M441). Os fármacos predictos pelo C-MAP foram eficazes na diminuição da proliferação 
celular in vitro bem como na redução do crescimento tumoral e no aumento da sobrevida em 
ratinhos com meduloblastomas do Grupo 3 implantados no cerebelo. O composto 
alsterpaullone revelou-se o mais eficaz, quer in vitro quer in vivo, na linha celular pluripotente 
obtida de um doente. É interessante salientar que a caracterização do perfil químico e 
genómico de células de meduloblastoma do Grupo 3 tratadas com alsterpaullone confirmou a 
inibição de genes relacionados com o ciclo celular e a regulação negativa de MYC, o 
oncogene característico dos meduloblastomas do Grupo 3. 
 
 Usámos no nosso estudo uma abordagem com base na expressão genética para 
identificar terapêuticas dirigidas para o tratamento do meduloblastoma. Os resultados 
apresentados demonstram a eficácia pré-clínica de duas pequenas moléculas inibidoras: 
foretinib para o tratamento do meduloblastoma metastático do tipo SHH e alsterpaullone para 
o tratamento de meduloblastomas do Grupo 3. Tendo em conta o prognóstico sombrio e a 
falta de opções terapêuticas nestes doentes, os resultados dos nossos estudos constituem forte 
evidência para que estes compostos sejam incluídos como terapias dirigidas em ensaios 
clínicos para doentes diagnosticados com estes subgrupos agressivos de meduloblastoma. 
 
 
 
Palavras-chave: subgrupos de meduloblastoma, genómica, via de sinalização HGF/cMET, 
foretinib, alsterpaullone  
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Chapter 1  
Introduction 
 
1.1 The Genomic Landscape of Medulloblastomai 
Medulloblastoma is the most common malignant brain tumor in childhood, 
comprising 20% of all primary pediatric brain tumors, although it can arise from infancy to 
adulthood1. The incidence of medulloblastoma in children has been estimated between 5.0 
and 6.6 per million per year2,3 and in adults between 0.57 and 0.58 per million per year4. The 
current treatment protocol for medulloblastoma includes surgical resection, radiation (for 
children older than 3 years of age) and chemotherapy with 5-year survival rates ranging 
between 50 and 80%. Among long-term survivors, a major concern is the sequelae induced by 
treatment including endocrinologic, neurocognitive and behavioral dysfunction5. 
Medulloblastoma arises in the cerebellum and originates from primitive pluripotent 
precursor cells of the ventricular zone and the external granular layer6. Medulloblastoma 
formation is strongly associated with dysregulation of pathways involved in the normal 
development of the cerebellum, including the Sonic hedgehog (SHH), Wingless (WNT) and 
Notch pathways7. 
The World Health Organization (WHO) classified medulloblastoma as a grade IV 
embryonal neoplasm comprising five histological variants: classic, desmoplastic/nodular, 
anaplastic, large cell and medulloblastoma with extensive nodularity8. Classic 
medulloblastomas are composed of densely packed, poorly differentiated cells, and areas of 
                                                
i Claudia C. Faria, Christian A. Smith and James T. Rutka (2013). New Molecular Targets and Treatments for 
Pediatric Brain Tumors, Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications, 
Dr. Terry Lichtor (Ed.), ISBN: 978-953-51-0989-1, InTech, DOI: 10.5772/53300. 
Claudia C. Faria, Yuzo Terakawa and James T. Rutka (2014). Neurogenetic Basis of Pediatric Neurosurgical 
Conditions, Principles and Practice of Pediatric Neurosurgery, 3rd ed, Leland Albright, Ian F. Pollack, P. David 
Adelson (Editors), Thieme Medical Publishers (in press). 
 
 
Using Genomics for Drug Discovery in Medulloblastoma 
 32 
Homer-Wright rosettes. The desmoplastic/nodular variant includes pale nodular areas (pale 
islands) with patterns of neuronal differentiation surrounded by hyperchromatic cells densely 
packed. Anaplastic medulloblastomas are characterized by large pleomorphic nuclei. Tumor 
cell “wrapping” and mitotic figures are abundant. Large cell tumors are composed of enlarged 
round cells with prominent nuclei and pronounced mitotic and apoptotic figures. Tumors with 
both large cell and anaplastic regions can be encountered. Medulloblastoma with extensive 
nodularity shows a lobular architecture with long reticulin-free areas between the nodules. 
Clinical studies suggest a favorable outcome associated with desmoplastic medulloblastoma 
and a significant worst prognosis with the anaplastic subtype9. 
Medulloblastoma has been reported in the setting of several hereditary cancer 
syndromes including Li-Fraumeni syndrome, Gorlin syndrome, Turcot syndrome and 
Rubinstein–Taybi syndrome10. The Li-Fraumeni syndrome is associated with germline 
mutations in the TP53 gene. Among many other cancers, patients with Li-Fraumeni syndrome 
have an increased risk to develop embryonal tumors (including medulloblastoma) and choroid 
plexus carcinoma. Gorlin syndrome (nevoid basal cell carcinoma syndrome) patients have 
germline mutations in the PTCH1 gene, a component of the SHH signaling pathway, and up 
to a 5% risk of developing medulloblastoma. Germline mutations in the SUFU gene, a 
downstream mediator of the SHH pathway, have also been shown in patients with 
medulloblastoma11. Germline mutations of the APC gene, a component of the WNT signaling 
pathway, are seen in patients with Turcot syndrome who have an increased risk for colorectal 
carcinoma and brain tumors, predominantly medulloblastoma. Children with Rubinstein-
Taybi syndrome have a complex developmental disorder that includes broad thumbs and toes, 
characteristic facies, severe developmental delay, and a predisposition to malignancy, 
including medulloblastoma, oligodendroglioma and meningioma. This syndrome is secondary 
to deletion/mutation of the Crebs binding protein (CBP) gene which functions in three 
pathways involved in medulloblastoma pathogenesis (SHH, WNT and TP53)12. 
Recent efforts of multiple independent groups have reached to a consensus that 
medulloblastoma comprises four distinct molecular variants named WNT, SHH, Group 3 and 
Group 413. The subgroups have different demographics, genetic profiles and prognosis14. This 
may explain why patients with the same histological disease have different clinical outcomes 
and a variable response to current treatments including surgery, whole-brain radiation and 
intensive chemotherapy. Figure 1.1 summarizes the main features of the four 
medulloblastoma subgroups. 
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1.1.1 WNT Medulloblastomas 
WNT medulloblastomas are frequent in older children and teenagers and are rarely 
seen in infants. Patients within this subgroup have usually a very good outcome with survival 
rates over 90%. However, Remke et al. showed that this is only true for pediatric cases as 
adult WNT patients exhibit survival rates of approximately 80%15. Histologically, WNT 
tumors are almost always of the classic variant and they rarely disseminate.  
 
 
Figure 1.1: Features of the four medulloblastoma subgroups, including molecular genetics 
and clinical outcome. 
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This subgroup is enriched in genes of the WNT pathway. Specifically gene expression 
changes involve a combination of increased expression of inhibitors of WNT signaling (e.g. 
WIF1, DKK1, DKK2, AXIN2) and potential promoters of WNT signaling (e.g. WNT16, 
LEF1)16. CTNNB1 mutation is the most common genetic event in WNT medulloblastomas 
and promotes the accumulation of β-catenin in the nucleus. Positive nuclear immunostaining 
for β-catenin is now routinely used as a marker of WNT pathway activation and is associated 
with better survival rates17. After CTNNB1, the DDX3X (DEAD-box RNA helicase) gene is 
the most frequently mutated in medulloblastoma and occurs in 50% of WNT tumors18. WNT 
medulloblastomas often carry TP53 mutations and they confer a more favourable outcome19. 
Almost all patients with WNT medulloblastomas have monosomy 6 (deletion of one copy of 
chromosome 6), although the role of this chromosomal aberration remains undefined20. 
Recently, a mouse model of WNT medulloblastoma was generated and the cell of 
origin for this subgroup was elucidated. Mice with transgenic expression of a CTNNB1 
mutation in the context of a TP53 deletion developed classic medulloblastoma, arising from 
progenitor cells in the lower rhombic lip of the dorsal brainstem21. 
The overall favourable outcome of WNT tumors suggests that this subgroup of 
patients may be considered for the de-escalation of therapy in future clinical trials. 
 
1.1.2 SHH Medulloblastomas 
SHH medulloblastomas have an intermediate prognosis with a 5-year overall survival 
(OS) of approximately 75%. Age distribution in these tumors is bimodal. They are frequently 
found in infants and adults but are rare in childhood. Prognostic factors such as desmoplasia 
and metastatic status are age-dependent. Desmoplasia is associated with a poor outcome only 
in children, while metastasis at presentation constitutes a negative prognostic factor only in 
adults22. SHH medulloblastomas include tumors of the four main histological variants 
(classic, nodular desmoplastic, large-cell anaplastic and medulloblastoma with extensive 
nodularity), although nodular desmoplastic histology is almost exclusively seen in this 
subgroup. 
SHH-driven medulloblastomas exhibit aberrant expression of SHH pathway genes 
including PTCH1, SUFU, SMO and GLI2. Germline mutations affecting PTCH1 or SUFU 
predispose patients with Gorlin syndrome to develop medulloblastoma. Amplifications and 
somatic copy number aberrations (CNAs) of SHH target genes such as MYCN and GLI2 are 
also seen in this subgroup. An interesting association of SHH medulloblastoma and 
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deregulation of the PI3K signaling pathway has been recently reported. The alterations 
include amplifications of insulin-like growth factor 1 receptor (IGF1R) and focal deletions of 
PTEN23. When compared to WNT medulloblastoma genome, the SHH subgroup contains 
significant more gains and losses of chromosomal regions, including deletion of chromosome 
9q and 10q. In an attempt to simplify the molecular subgrouping of medulloblastomas, 
different laboratories used formalin-fixed paraffin-embedded tissues (FFPE) to test a variety 
of markers for SHH medulloblastomas including SFRP1, GLI1 and GAB116,24,25. 
Of note is the fact that the transcriptomes of pediatric and adult SHH tumors have 
different expression profiles with increased levels of genes related to extracellular matrix 
function in the first group and elevated levels of HOX family genes and genes involved in 
tissue development in the second group22,26. The clinical and molecular distinction of infant 
and adult SHH medulloblastomas suggests a disparate underlying biology and raise the 
question of possible different responses to current targeted therapies. 
The cells of origin of SHH medulloblastoma are the cerebellar granule neuron 
precursors (CGNPs) of the external granule cell layer (EGL) of the cerebellum27 and those of 
the cochlear nuclei of the brainstem28. SHH medulloblastomas can also be initiated from 
neural stem cells in the subventricular zone29. 
Several mouse models of SHH-dependent medulloblastoma are available for basic and 
preclinical research. The most common initiating events in these models include Ptch1 
inactivation and smoothened (Smoa1) activation18. 
 
1.1.3 Group 3 Medulloblastomas 
Group 3 medulloblastomas have the worst prognosis of all subgroups. These tumors 
are restricted to children and infants, frequently have a large-cell anaplastic histology and 40 
to 45% are disseminated at the time of diagnosis. One of the features of this subgroup is the 
amplification of MYC. In a recent study including a cohort of over 1,000 medulloblastoma 
samples, Northcott et al. identified recurrent fusions involving MYC and PVT1 in about 60% 
of MYC-amplified tumors23. PVT1 gene is adjacent to MYC on chromosome 8q24.21 and 
encodes several microRNAs that seem to promote MYC oncogenic properties30. This study 
also identified for the first time the TGF-β pathway as a potential target in Group 3 
medulloblastoma. The genome of Group 3 tumors is highly unstable often exhibiting gains in 
chromosomes 1q, 7 and 17q (frequently isochromosome 17q), as well as deletions in 
chromosomes 10q, 11, 16q and 17p.  
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Recently, mouse models of MYC-driven Group 3 medulloblastoma, combined with 
Trp53 inactivation, were published. The cells of origin of these tumors were prominin 1-
positive, lineage-negative neural stem cells and the CGNPs of the EGL31,32. Since TP53 
mutations are not seen in Group 3 medulloblastomas other candidates to cooperate with MYC 
in the process of tumorigenesis are being studied. 
 
1.1.4 Group 4 Medulloblastomas 
The most common medulloblastoma subgroup is Group 4 and, curiously, it is the least 
well understood. Group 4 tumors can be found across all age groups although children have 
an intermediate prognosis while adults may do significantly worse15. The expression of 
follistatin-related protein 5 (FSTL5) was identified as a marker of high-risk Group 4 
patients33. These tumors are usually of the classic variant and show dissemination in one third 
of the patients. Recurrent amplifications of MYCN and cyclin-dependent kinase 6 (CDK6) are 
frequent in this subgroup as well as isochromosome 17q (i17q). Recently, a novel and 
frequent somatic CNA was described in Group 4 medulloblastomas. It is a duplication of 
SNCAIP, a gene involved in Parkinson’s disease and located on chromosome 5q23.2.  
Duplication of SNCAIP is restricted to Group4α, a subtype of Group 4 medulloblastoma with 
a mostly balanced genome23. The NF-κB pathway was also identified as a new targetable 
pathway in this subgroup of tumors. However, there are currently no mouse models of Group 
4 tumors and its cell of origin is still unknown. 
 
 
Despite the potential for prognostic subgrouping based on molecular signatures or 
immunohistochemistry, clinical application of these findings is in its infancy. No consensus 
on a prognostic algorithm currently exists, although efforts to merge clinical and molecular 
features for risk stratification in clinical trials is underway. 
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1.2 The Role of HGF/cMET Pathway Signaling in Human 
Medulloblastomaii 
 Medulloblastoma is associated with dysregulation of pathways that normally lead to 
cerebellum development. Over the past few years, different signaling pathways have been 
shown to play a critical role in medulloblastoma formation and progression. The hepatocyte 
growth factor (HGF)/cMET signaling pathway has been implicated in different processes 
including development and tumorigenesis but only recently has it been demonstrated in 
medulloblastoma pathogenesis. The receptor tyrosine kinase cMET is normally activated by 
ligation through its ligand HGF, secreted as a precursor that is proteolytically cleaved in an 
active form by the serine protease hepatocyte growth factor activator. HGF is a member of the 
plasminogen-related growth factor family and was originally identified as a growth factor for 
hepatocytes and as a fibroblast-derived cell motility or scatter factor. The interplay between 
cMET and its ligand mediate downstream events that, in the central nervous system, play a 
critical role in cerebellar granule cell precursors proliferation and survival. Dysregulation of 
this pathway can promote tumorigenesis through cell migration, invasion and metastasis, 
angiogenesis and prevention from apoptosis. cMET has been found to be overexpressed in a 
variety of malignancies where its activation can occur by HGF ligation or through ligand 
independent mechanisms, including mutations and amplifications. 
 It was shown that medulloblastoma tumor cell lines and surgical tumor samples express 
HGF and cMET. Furthermore, overexpression of cMET is associated with poor clinical 
outcome. Treatment of medulloblastoma cell lines with HGF induced tumor cell proliferation, 
anchorage-independent growth and reduced apoptosis in response to chemotherapy. SPINT2, 
a tumor supressor gene silenced by promoter methylation in medulloblastoma, was identified 
by our group as a key regulator of HGF/cMET pathway34. Several therapeutic strategies 
aiming to target and limit the signaling cascade of HGF/cMET were examined with the cMET 
inhibitors being the most promising. Targeting the HGF/cMET pathway, alone or in 
combination with standard therapies is likely to improve present treatments in MET-
dependent malignancies such as medulloblastoma. 
                                                
ii Claudia Faria, Christian Smith and James Rutka (2011). The Role of HGF/c-Met Pathway Signaling in Human 
Medulloblastoma, Molecular Targets of CNS Tumors, Dr. Miklos Garami (Ed.), ISBN: 978-953-307-736-9, 
InTech, DOI: 10.5772/23296. 
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1.2.1 The HGF/cMET Pathway Signaling 
 The HGF/cMET pathway has been associated with normal development, organ 
regeneration and cancer. cMET is a high affinity tyrosine kinase receptor for hepatocyte 
growth factor (also known as scatter factor, capable of inducing dissociation and motility). 
cMET is generally expressed in epithelial cells and is activated by HGF produced in 
surrounding mesenchymal cells or released into the circulation.  
 During embryogenesis the HGF/cMET signaling is necessary for the development of 
the placenta, liver, kidney and neuronal tissue but also for the directional migration of skeletal 
muscle cells35. In adult tissues, this pathway has been implicated in regeneration and wound 
healing36,37. Therefore, the HGF/cMET axis is a key player in cell proliferation, survival and 
migration and, when dysregulated, can give origin to a variety of cancers. 
 
1.2.1.1 Structure of HGF and cMET 
HGF is a multidomain protein similar to plasminogen, a circulating proenzyme that 
promotes the lysis of fibrin blood clots in its active form as plasmin. HGF is synthesized as a 
single-chain inactive precursor and it is converted by serine proteases into an active form with 
two chains (α and β chain) linked by a disulfide bond. HGF consists of six domains: an 
amino-terminal hairpin loop domain, four kringle domains (K1-K4) and a serine protease 
homology (SPH) domain which lacks enzymatic activity (Figure 1.2). 
cMET, the HGF receptor, is a disulfide-linked heterodimer which results from 
cleavage of a precursor into an extracellular α chain and a transmembrane β chain. The 
extracellular region of cMET is composed of three domains: the Sema domain (homologous 
to the Sema domain of the semaphorins and plexins) that includes the entire α chain and part 
of the β chain; the PSI domain (also present in the plexins, semaphorins and integrins); and 
four IPT domains (immunoglobulin-like also found in plexins and transcriptional factors). 
The intracellular region of cMET consists of three portions: a juxtamembrane sequence that 
has the role to downregulate kinase activity upon phosphorylation of Ser975; a catalytic 
region that activates kinase activity following phosphorylation of Tyr1234 and Tyr1235; and 
a carboxy-terminal multifunctional docking site that contains two docking tyrosines (Tyr1349 
and Tyr1356) essential for downstream signaling38. 
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Figure 1.2: HGF and cMET structures.  
 
 
1.2.1.2 cMET Signal Transduction 
To activate the cMET receptor, the single chain HGF precursor is cleaved into a 
heterodimeric active form by a protease called HGF activator (HGFA)39. This process is 
regulated by a protein family of serine protease inhibitors called SPINT1 and SPINT240,41. 
Inhibiting the activation of HGF by HGFA, SPINT1 and -2 limit signaling through the 
HGF/cMET pathway. 
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Following HGF binding, the kinase activity of cMET is switched on. This process 
starts with receptor dimerization and trans-phosphorylation of two tyrosine residues in the 
catalytic region (Tyr1234 and Tyr1235) and is followed by phosphorylation of two additional 
tyrosines in the carboxy-terminal tail (Tyr1349 and Tyr1356). These tyrosines create docking 
sites for a variety of adaptor proteins and direct kinase substrates including the growth factor 
receptor-bound protein 2 (GRB2), Grb2-associated adaptor protein (GAB1), son of sevenless 
(SOS), SRC homology protein tyrosine phosphatase 3 (SHP2), phosphatidylinositol-3-kinase 
(PI3K) and signal transducer and activator of transcription 3 (STAT3). This leads to the 
activation of downstream signaling pathways that include the mitogen-activated protein 
kinase (MAPK), PI3K/AKT and STAT pathways, which mediate cMET-dependent cell 
proliferation, survival, migration and invasion (Figure 1.3). 
 
 
Figure 1.3: The HGF/cMET signaling pathway. 
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The activation of MAPK cascade will sequentially activate different protein kinases 
whose terminal effectors include extracellular signal-regulated kinases (ERK1 and ERK2), 
jun amino-terminal kinases (JNK1, JNK2 and JNK3) and p38. These downstream elements 
will activate cell cycle regulators leading to cell proliferation and will promote alterations in 
cytoskeletal functions that control cell migration and invasion. PI3K/AKT activation mediates 
cell survival and resistance to apoptosis through inactivation of the pro-apoptotic protein 
BCL-2 antagonist of cell death (BAD) and degradation of the pro-apoptotic protein p5342. 
Upon activation of STAT3 by the cMET receptor at the plasma membrane, it translocates to 
the nucleus to operate as a transcription factor regulating the expression of genes implicated 
in cell proliferation and differentiation43. 
Other molecules that interact with the cMET receptor include the epidermal growth factor 
receptor (EGFR), the α6β4 integrin, the semaphoring receptors of the plexin B family and the 
variant of the hyaluronan receptor CD44 (that links the extracellular matrix and the 
intracellular cytoskeleton)44-46. This crosstalk of cMET with different surface proteins 
highlights the dynamic environment at the plasma membrane and contributes to cMET 
associated biological responses47. 
 
1.2.1.3 Regulation of cMET Signaling 
It has been shown that the signaling network around the tyrosine kinase receptor 
cMET is more complex than the known process of recruiting signaling effectors at the plasma 
membrane and subsequently stimulating intermediates in the cytosol. In fact, this view has 
been expanded by the finding that cMET signals can also originate from endosomal 
compartments and by a series of other events. 
Upon HGF binding, cMET is internalized by clathrin-mediated endocytosis and 
recruited into peripheral early endosomes. This process is mediated by protein kinase Cε 
(PKCε) that promotes the transfer of active ERK to focal adhesions and, subsequently, the 
HGF-induced cell migration. From the peripheral endosomes, cMET travels along the 
microtubule network to late perinuclear compartments in a process mediated by PKCα. This 
juxtanuclear accumulation of cMET is a determinant step for activation and nuclear 
translocation of STAT348,49.  
Downregulation of cMET signaling involves trafficking and degradation of ligand-
activated receptors in the lysosomes. This process is initiated by the association of cMET with 
casitas B-lineage lymphoma (CBL) and endocytic adaptors. Following endocytosis, cMET 
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accumulates in multivesicular bodies that later fuse with lysosomes and lead to protein 
degradation. cMET can also undergo sequential proteolytic cleavage at two juxtamembrane 
sites. The first cleavage occurs in the extracellular domain and is mediated by a desintegrin 
and metalloprotease (ADAM) originating a ‘decoy’ fragment that sequesters the ligand and 
interferes with the receptor’s activity. The second cleavage is performed in the intracellular 
domain, by a γ-secretase and yields a fragment that is destroyed in the proteasome50 (Figure 
1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Mechanisms of cMET signaling regulation. 
 
 
1.2.2 HGF, cMET and Cancer 
The dysregulation of HGF/cMET signaling has emerged as a key player in several 
human malignancies, particularly in invasion and metastasis. Human cell lines overexpressing 
either HGF and/or cMET become tumorigenic and metastatic when implanted into nude 
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mice51. Moreover, transgenic mice expressing the receptor or the ligand develop metastatic 
tumors52. On the contrary, downregulation of HGF or cMET expression in human tumor 
xenografts decreases tumor growth53. There are three biological mechanisms underlying the 
tumorigenicity of cMET: a) the establishment of HGF/cMET autocrine loops; b) the 
overexpression of HGF or cMET; and c) the presence of activating mutations in the cMET 
receptor54. 
An autocrine mechanism of cMET activation is found in some human tumors. For 
example, osteosarcomas and rabdomyosarcomas are derived from mesenchymal cells which 
physiologically produce HGF. Glioblastomas and breast carcinomas are derived from 
ectodermal tissues that normally express cMET but not HGF. Experimental models of 
HGF/cMET autocrine loops were also able to generate invasive tumors in vitro and in 
transgenic mice55 
The most frequent mechanism of cMET dysregulation found in human tumors is the 
overexpression of the receptor or its ligand. A large number of studies showed that HGF and 
cMET are expressed in a wide variety of human tumors and in their metastasis. These include 
carcinomas of the breast, colon, lung, ovary, liver, kidney, upper gastrointestinal tract, 
pancreas and prostate but also sarcomas, haematopoietic malignancies, melanomas and 
glioblastomas42. 
It has also been shown that high expression levels of cMET and its ligand correlate 
with increased aggressiveness of tumors and patients poor prognosis42. For example, in 
colorectal cancer patients, cMET is a powerful prognostic factor for early stage invasion and 
metastasis56. Moreover, in a study including 74 clinical samples of low-grade and high-grade 
gliomas the authors described a correlation of HGF and cMET expression levels with tumor 
grade57. 
The compelling evidence that links cMET with human cancer relies in the cMET-
activating mutations found in hereditary renal papillary carcinoma. These mutations were also 
found in sporadic tumors such as renal carcinoma, gastric cancer, childhood hepatocellular 
carcinoma and in head and neck squamous cell carcinomas47,55.  
The association between cancer and blood coagulation disorders has been known for 
many years. In fact, approximately 50% of all patients with malignant tumors and up to 90% 
of those with metastasis have coagulopathies58. Interestingly, Boccaccio et al. showed in a 
mouse model that activation of the oncogene cMET induced cancer and a trombohemorrhagic 
syndrome through transcriptional upregulation of the procoagulation factors plasminogen 
activator inhibitor type 1 (PAI-1) and cyclooxygenase-2 (COX-2). Upon a first phase 
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characterized by a hypercoagulation state due to cMET signaling activation, the mice 
developed a hemorrhagic diathesis due to exhaustion of the hyperactivated hemostatic 
system59. At the early step of this process, hypoxia induces transcription of cMET that, 
subsequently, activates the transcription of genes involved in hemostasis, such as PAI-1 and 
COX-2. The activation of the coagulation cascade will lead to fibrin deposition around cells 
forming an extracellular matrix that will promote angiogenesis and cell migration60. 
HGF/cMET signaling has also a role in angiogenesis either by direct influence of 
cMET activation in vascular endothelial cells, or by regulation of the expression levels of 
other angiogenic factors in tumor cells. It was previously shown that the HGF/cMET 
interaction stimulates proliferation and migration of endothelial cells in vitro and induces 
blood vessel formation in vivo61. Zhang et al. described the “angiogenic switch” in tumor 
cells upon HGF stimulation by simultaneous upregulation of the proangiogenic vascular 
endothelial growth factor (VEGF) and downregulation of thrombospondin 1 (TSP-1), an 
angiogenesis inhibitor62. This process has distinct mediators: while VEGF is modulated by 
MAPK, PI3K and STAT3, TSP-1 is targeted only by MAPK. An interesting example of this 
regulation was found in human glioma cells where stimulation with HGF increased the 
expression levels of VEGF and tumor-associated angiogenesis. The use of HGF and cMET 
inhibitors in experimental tumor models significantly reduced tumor growth and tumor vessel 
formation57. Recently, a new key player of the HGF/cMET pathway was described. 
Metastasis-associated in colon cancer-1 (MACC1) was identified by genome-wide expression 
analysis in primary and metastatic colon carcinomas. Its expression in human tumor samples 
was found to be an independent prognostic factor for metastasis formation and metastasis-free 
survival. The experimental studies showed that MACC1 promotes proliferation, invasion and 
HGF-induced scattering in vitro and tumor growth and metastasis in xenograft models63. The 
authors proposed a positive feedback mechanism where MACC1 acts as a transcriptional 
regulator of the cMET gene. The stimulation of the cMET receptor with HGF causes the 
translocation of MACC1 from the cytoplasm into the nucleus. There, MACC1 activates the 
transcription of the cMET gene by binding to its promoter64. The increased amounts of cMET 
receptor will be able to bind more HGF molecules thereby enhancing the pathway signaling 
and promoting cell proliferation, migration and metastasis. 
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1.2.3 HGF/cMET Signaling in Medulloblastoma 
 
1.2.3.1 HGF/cMET Pathway in Cerebellar Development 
During embryonic development, the progenitor cells localized in the ventricular zone 
of the cerebellum (also called primary germinal zone), along the fourth ventricle, migrate 
radially to give rise to Purkinje cells, neurons of the cerebellar nuclei and different types of 
cerebellar interneurons. Simultaneously, the progenitor cells in the rombic lip migrate 
dorsally to originate in the EGL or secondary germinal zone. The peak of proliferation of 
these cells occurs between postnatal day (P) P5 and P8 in the mouse. Through a tightly 
regulated mechanism, the progenitor cells in the EGL become postmitotic, differentiate and 
migrate inwards to give origin to the internal granule layer (IGL), a process that is compete by 
P20 in the mouse65. 
During the early postnatal period, multiple mitogenic pathways, such as SHH, WNT 
and Notch, promote the rapid expansion of progenitor cells in the EGL. It is believed that this 
vast population of cells includes subgroups of progenitors with distinct genetic properties, that 
give origin to the different medulloblastoma subtypes7. 
The HGF/cMET pathway also plays a critical role in cerebellar development. The 
knockout mice for HGF, cMET and SPINT2 are all embryonic lethal66-68. Comparing the 
regional expression of HGF and cMET in both developing and adult rat brains, Achim and 
co-workers found expression of HGF in the parietal cortex, striatum and cerebellar deep gray 
matter in developing but not in adult brain. Abundant expression of cMET was also detected 
in the newborn cortex, thalamus and brainstem69. The analysis of HGF and cMET expression 
in the central nervous system of different mammalian species showed that their neuronal 
expression is highly conserved during evolution, a sign that they mediate important 
functions70. 
Leraci et al. described the expression of cMET in the proliferating cells of the external 
granule layer of the cerebellum and increased proliferation after stimulation of primary 
cultures of granule cells with HGF. In addition, transgenic mice with partial loss of cMET 
function had a smaller cerebellum with abnormal foliation and balance impairment71. HGF 
has also been proposed to mediate neurotrophic functions during neurogenesis both in the 
central and peripheral nervous systems. In fact, it was shown that HGF is a chemoattractant 
and promotes survival of motor neurons in the embryo. Furthermore, stimulation of sensory 
and sympathetic neurons with HGF enhances survival, differentiation and axonal growth72. 
Using Genomics for Drug Discovery in Medulloblastoma 
 46 
Exploring the neuroprotective role of HGF, different groups showed that HGF treatment of 
primary cerebellar granule neurons prevents apoptotic cell death through activation of the 
PI3K/AKT pathway signaling73-75. 
 
 
1.2.3.2 HGF/cMET Pathway in Medulloblastoma Formation 
HGF/cMET signaling has an important role in tumorigenesis and metastatic behavior 
in several human malignancies but its role in medulloblastoma pathogenesis was only 
recently described.  
Studying a series of 14 human medulloblastoma samples by comparative genomic 
hybridization Tong et al. found amplification of the cMET oncogene on chromosome 7q in 
38.5% of cases76. Other group showed a correlation between the expression of HGF and 
cMET in human medulloblastoma samples and patient clinical outcome77. When they 
stimulated medulloblastoma cells with HGF there was an activation of downstream effectors, 
evidenced by cMET, MAPK and AKT phosphorylation. Up-regulation of the pathway was 
also able to induce cell proliferation, cell cycle progression, anchorage-independent growth 
and resistance to chemotherapy-induced apoptosis in medulloblastoma cell lines. In vivo 
models overexpressing HGF also had increased tumor growth and invasion77. More recently, 
the same group identified an association between HGF/cMET signaling and c-MYC in 
medulloblastoma. They found that HGF induced MYC expression both at transcriptional and 
post-transcriptional levels, leading to cell cycle progression, cell proliferation and apoptosis78. 
Although the anti-apoptotic functions of HGF/cMET pathway seem to be 
predominant, Li et al. described enhanced cell death in Daoy cell lines after cMET activation. 
Apoptotic cell death can be induced by two different pathways: the intrinsic mitochondrial 
pathway and the extrinsic death receptor pathway. In malignant tissues, the tumor necrosis 
factor-related apoptosis–inducing ligand (TRAIL) has the potential to activate the death 
receptor pathway upon binding of death receptors DR4 and DR5, which leads to downstream 
caspase activation and apoptosis79. Li and co-workers found that increased apoptosis of 
medulloblastoma cell lines after stimulation with HGF was induced by TRAIL and mediated 
by DR5 overexpression80. Moreover, the treatment of those cells with a specific cMET 
inhibitor (PHA665752) reduced apoptosis indicating that it requires activation of the 
canonical receptor tyrosine kinase80. 
Using an epigenome-wide screening our group identified an inhibitor of HGF/cMET 
signaling. SPINT2, a tumor suppressor gene, was downregulated in 73.2% of primary 
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medulloblastoma samples while cMET was upregulated in 45% of cases. SPINT2 was 
silenced by promoter hypermethylation in 34.4% of primary tumor samples34. A single 
nucleotide polymorphism (SNP) array analysis identified hemizygous deletions in the SPINT2 
locus on chromosome 19q13.2 and gains in the HGF and cMET loci on chromosome 7q. The 
experimental studies using medulloblastoma cells transfected with SPINT2 showed decreased 
proliferation, migration and anchorage-independent growth in vitro and increased survival 
times in mouse xenografts34. Although SPINT2 downregulation has already been implicated 
in other human cancers81-83 this was the first report to establish its role in medulloblastoma 
pathogenesis.  
Binning et al. showed that HGF and SHH cooperate to transform cerebellar neural 
progenitors in transgenic mice, leading to medulloblastoma initiation and growth. 
Furthermore, the treatment of mice bearing SHH+HGF induced tumors with a monoclonal 
antibody against HGF (L2G7) prolonged survival by increasing apoptosis84. Previous studies 
had already shown that systemic administration of L2G7 to mouse xenografts of human 
HGF+/cMET+ glioblastomas improved survival and reduced tumor growth85. 
Knowing that a procoagulant state is often the first manifestation of a malignancy and 
that it is due to the expression of specific proteins such as tissue factor (TF), Provencal and 
colleagues analyzed the expression of this protein in human medulloblastoma samples and 
observed a strong correlation between cMET and TF expression levels. Furthermore, the 
stimulation of Daoy cells with HGF increased the expression of TF and the treatment of those 
cells with physiological amounts of TF activator (factor VIIa) increased their migratory 
potential86. It was hypothesized that the acquisition of a procoagulant phenotype by 
medulloblastoma favors its dissemination because the enrichment of the tumor environment 
with fibrin protects the cancer cells from the immune system and forms a matrix for cell 
migration86. The same group found that upregulation of TF upon cMET pathway activation 
was associated with increased resistance to the chemotherapeutic drug etoposide87. This 
observation suggested that the combination of anticoagulant drugs and chemotherapy could 
improve the efficacy of chemotherapeutic agents. In fact, this regimen was already tested in 
metastatic breast cancer with encouraging results88. 
These findings show the importance of the HGF/cMET pathway signaling in 
medulloblastoma malignancy. Furthermore, they also provide validation of this pathway as a 
target for new and promising therapies using small molecular inhibitors and antibodies, some 
of them already in clinical trials for other cancers. 
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1.2.4 Inhibitors of HGF/cMET Pathway in Cancer Therapy 
The evidence that the HGF/cMET pathway is involved in the progression and 
dissemination of several malignancies has generated considerable interest in HGF and cMET 
as major targets in cancer therapy and drug development. Different strategies are being 
explored and some of them are already being tested in clinical trials. We can consider three 
main groups of drugs: a) HGF and cMET antagonists or competitors; b) Monoclonal 
antibodies directed against HGF and cMET; and c) Small molecule tyrosine kinase inhibitors. 
The use of molecular targeted therapies against HGF and cMET in medulloblastoma 
was only recently reported. Our group demonstrated the efficacy of a highly specific small 
molecular inhibitor (PHA665752) in the treatment of medulloblastoma cell lines by reducing 
cell proliferation, migration and anchorage-independent growth89. Another group used an 
orally available small molecule inhibitor of cMET (SGX523) in medulloblastoma cells and 
human glioblastoma xenografts. They reported decreased cell proliferation, migration and 
invasion in the in vitro studies and significant reduction of in vivo tumor growth90. The HGF-
neutralizing monoclonal antibody, L2G7, was also tested in monotherapy and in combination 
therapy in genetically engineered mice with medulloblastomas induced by SHH and HGF. 
The authors reported tumor growth inhibition and increased survival with L2G7 
monotherapy91. 
Strategies using combined regimens targeting multiple receptor tyrosine kinases are 
currently under study. This can be achieved in two different ways either by a combination of 
highly selective agents or by using a single agent that targets multiple specific members of the 
cMET pathway. The use of broad-spectrum agents may have the advantage of reducing drug 
interactions, but it may also affect other unintended kinases. Stommel et al., studying glioma 
cell lines, xenografts and human primary glioblastomas, showed simultaneous activation of 
multiple receptor tyrosine kinases and better responses to combined treatment when compared 
to monotherapy92. 
We provide a brief summary of the latest advances in HGF/cMET targeted therapy 
(Table 1.1). 
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Table 1.1: Summary of the HGF/cMET inhibitors. 
Compound Mechanism of Action 
Stage of 
development References 
Biological antagonists 
NK2 Inhibits HGF activity Preclinical 93,94 
NK4 Inhibits HGF binding to cMET Preclinical 
95-97 
Uncleavable HGF Inhibits proteolytic HGF activation Preclinical 
98 
    
Decoy MET Inhibits HGF binding and cMET dimerization Preclinical 
99 
Antibodies 
AMG102 (Amgen) Anti-HGF (IgG2) Phase II trial 100-102 
L2G7 (Galaxy Biotech) Anti-HGF (IgG1) Preclinical 
85,91,103 
 
MetMAb (Genentech) Anti-cMET Phase II trial 104 
Small molecule inhibitors of cMET 
PHA665752 (Pfizer) Selective inhibitor (cMET) Preclinical 
78,89 
PF2341066 (Pfizer) Selective inhibitor (cMET and ALK) Phase II/III 
105-107 
ARQ197 (ArQule) Selective inhibitor (cMET) Phase II 
108,109 
SGX523 (SGX 
Pharmaceuticals) 
Selective inhibitor 
(cMET) 
Phase I 
(discontinued) 
90,110 
XL184 (Exelixis) 
Multikinase inhibitor 
(cMET, VEGFR, Ret, 
Kit, Flt-3, Tie-2) 
Phase II/III (http://clinicaltrials.gov) 
XL880 (Exelixis) 
Multikinase inhibitor 
(cMET, VEGFR, 
PDGFR, Ron, Kit, Flt-
3, Tie-2) 
Phase II 
111 
(http://clinicaltrials.gov) 
MP470 (Supergen) 
Multikinase inhibitor 
(cMET, PDGFR, Ret, 
Kit, Flt-3) 
Phase I 112-114 
VEGFR, vascular endothelial growth factor receptor; Ret, rearranged during transfection; Kit, 
stem cell factor receptor; Flt-3, FMS-like tyrosine kinase 3; Tie-2, angiopoietin receptor 2; 
PDGFR, platelet-derived growth factor receptor; Ron, recepteur d’origine nantais 
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1.2.4.1 HGF and cMET Antagonists 
HGF and cMET antagonists or decoys are molecules that bind to the receptor with 
high affinity without activation of downstream signaling. The activation of cMET by HGF 
implies the dimerization of the receptor upon binding of the two chains of the ligand. HGF 
has a high affinity site located in the α–chain and a low affinity site in the β–chain, which 
only becomes accessible after pro-HGF activation115. This means that the inactive form of 
HGF or HGF fragments can interact with cMET binding to the high affinity site but they 
cannot induce cMET signaling because they are unable to promote receptor dimerization.  
Examples of HFG competitors are NK2, NK4 and uncleavable HGF. NK2 is a 
naturally occurring HGF fragment and NK4 is a synthetic truncated form of HGF that 
contains only the α–chain. This is by far the best studied HGF antagonist and it was shown 
that it inhibits cell invasion and angiogenesis in vitro and in xenografts95.	  Uncleavable pro-
HGF is an unprocessable form of HGF that competes with active HGF for cMET binding and 
with pro-HGF proteases for HGF proteolytic activation. 
Decoy MET is an enzymatically inactive molecule that corresponds to the extracellular 
domain of the receptor. It interacts with HGF and full-length cMET, sequestering the ligand 
and interfering with the receptor dimerization. 
 
1.2.4.2 Monoclonal Antibodies Directed Against HGF and cMET 
The use of monoclonal antibodies has the following advantages: specificity against 
HGF and cMET; a relatively longer half-life when compared to other inhibitors; and the 
potential to induce a host immune response against the tumor cells116. 
AMG102 is a fully human IgG2 antibody against HGF that was found to enhance the 
effects of temozolomide and docetaxel in vitro and in xenograft models of gliomas101. A 
Phase I study used a combination of AMG102 and the antiangiogenic drugs bevacizumab and 
motesanib in the treatment of patients with advanced solid tumors, showing a stable disease in 
most patients117. This molecule has also been tested in Phase II clinical trials for advanced 
glioblastomas and renal cell carcinomas and a preliminary analysis in glioma patients 
suggested that AMG102 has limited efficacy as monotherapy118. Therefore, the most recent 
clinical trials will use AMG102 in combination therapy (http://clinicaltrials.gov). L2G7 is 
another anti-HGF antibody that proved to be effective reducing subcutaneous and intracranial 
glioma xenografts and to increase survival85. 
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The initial efforts to develop antibodies against cMET were unsuccessful because they 
tended to behave as agonists rather than antagonists, due to its bivalent structure that acts as a 
natural dimerizing agent. To circumvent this problem a ‘one-armed’ antibody (OA-5D5; 
MetMAb), consisting of a monovalent Fab fragment, was developed. It binds to cMET with 
high affinity preventing HGF interaction and subsequent downstream signaling. Martens et al. 
infused MetMAb intratumorally, reporting almost complete inhibition of tumor growth in a 
glioblastoma mouse model104. Phase II clinical trials using MetMAb in combination with 
bevacizumav and paclitaxel for metastatic breast cancer and with erlotinib for advanced non-
small cell lung cancer have been initiated (http://clinicaltrials.gov). 
 
1.2.4.3 Small Molecule Tyrosine Kinase Inhibitors  
 
Small molecule inhibitors target the ATP-binding site of the cMET receptor, blocking 
its transphosphorylation. These molecules can also be classified according to their specificity 
for cMET. Highly selective drugs may not be desirable as inhibition of multiple kinases may 
be more efficient and reduce the development of resistance. On the other hand, off-target 
inhibition of essential kinases may also be deleterious. With the recent advances in research 
and the ongoing clinical trials the small molecule inhibitors have emerged as promising 
drugs119. 
PHA665752 is a cMET selective inhibitor that was found to be effective in tumor cell 
lines and xenografts, particularly in a subset of cancers with amplification of the cMET 
gene89,120. Due to its low oral bioavailability another drug (PF2341066) with identical 
structure but more favorable pharmacokinetic properties was designed. PF2341066 
selectively targets cMET and anaplastic lymphoma kinase (ALK) and was shown to have 
antitumor cytoreductive activity and antiangiogenic activity in several cancer models105-107. A 
Phase II study in non-small-cell lung cancer reported encouraging results with a disease 
control rate of 87%121. The drug is now in Phase III trials. Interestingly, PF2341066 is also 
being tested in Phase I/II studies in children with recurrent solid tumors, primary central 
nervous system tumors and anaplastic large cell lymphoma (http://clinicaltrials.gov).     
ARQ197 is a highly selective, non-ATP competitive drug with reported clinical 
activity in several types of solid tumors. A Phase II trial in patients with non-small-cell lung 
cancer reported improved survival in patients treated with ARQ197 and erlotinib when 
compared to erlotinib monotherapy121. SGX523 is an orally available ATP-competitive 
molecule with high selectivity for Met. Although the initial results with in vitro and in vivo 
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models of medulloblastomas and gliomas looked promising because of its efficacy in 
reducing tumor growth, the drug was discontinued from a Phase I trial due to renal toxicity122. 
XL184 and XL880 are orally available, non-selective inhibitors, with high binding 
affinity to both cMET and VEGFR and to a lesser extent to other receptor tyrosine kinases 
such as PDGFR, Ret, Kit, Flt-3 and Tie-2123. XL184 is being evaluated in a Phase III study in 
patients with advanced medullary thyroid cancer and in Phase II studies in patients with 
glioblastoma multiforme and non-small-cell lung cancer that has progressed after previous 
benefit with erlotinib. XL880 has been tested in Phase II clinical trials in metastatic gastric 
cancer, papillary renal cell carcinoma and head and neck squamous cell cancer 
(http://clinicaltrials.gov). 
MP470 is a multi-kinase inhibitor, orally available, that was reported to radiosensitize 
glioblastoma cell lines, in vitro and in vivo models, through the suppression of RAD51, a 
DNA repair related protein113. Additional Phase I clinical studies used MP470 in 
monotherapy or in combination with standard chemotherapies in patients with metastatic solid 
tumors and lymphoma (http://clinicaltrials.gov). 
 
1.2.5 Conclusion and Future Directions 
The HGF/cMET signaling pathway plays a significant role in cancer and has emerged 
recently as a promising target in the treatment of several malignancies. It was shown that 
HGF and cMET are key players in cerebellum development and that their dysregulation is 
involved in medulloblastoma formation and progression.  
Advances in understanding the molecular mechanisms and genetic profiles underlying 
the different subtypes of medulloblastoma created an urgent need for new and less toxic 
targeted therapies. HGF/cMET inhibitors used in the treatment of gliomas in vitro and in vivo 
showed efficient reduction in tumor growth and are, therefore, being evaluated in clinical 
trials. Our preliminary data using a cMET selective inhibitor in medulloblastoma cell lines 
showed that the HGF/cMET pathway is a novel and promising therapeutic target in this 
disease. 
In the future we will test a panel of available HGF and cMET inhibitors using 
orthotopic xenograft models and our transgenic medulloblastoma mouse model. We hope that 
the results of our pre-clinical studies will provide the basis for future clinical trials where the 
HGF and cMET inhibitors could synergize with current therapies to increase survival and 
improve the quality of life of children with brain tumors. 
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1.3 Novel Therapies and Next Generation Clinical Trials in 
Medulloblastomaiii 
 
1.3.1 Advances in Medulloblastoma Clinical Trials 
The treatment of medulloblastoma includes surgery with maximal safe tumor 
resection and adjuvant chemotherapy with or without craniospinal irradiation, depending on 
patient age at diagnosis. Despite advances in these treatment modalities challenges remain to 
effectively treat some patients, especially those with recurrent or refractory medulloblastoma. 
Current medulloblastoma protocols separate children with standard-risk disease (absence of 
metastatic disease and residual tumor < 1.5 cm2) from those with high-risk disease (metastatic 
disease and/or residual tumor >1.5 cm2)124. More recently, the tumor histology was introduced 
in the staging system with patients with large cell/anaplastic histology being at greater risk of 
tumor relapse and hence, classified as high-risk125,126.  
Table 1.2 summarizes the most relevant clinical trials over the past years for standard-
risk, high-risk and recurrent medulloblastoma. 
 
1.3.1.1 Standard-risk patients 
The conventional treatment for standard-risk medulloblastoma has consisted of 
complete surgical resection followed by craniospinal radiation therapy with a total dose of 54-
56 Gy (36 Gy to the craniospinal axis with a boost of 18-20 Gy to the posterior fossa) and 
chemotherapy. The 5-year progression free survival using this therapeutic regimen was 
85%127. However, it has been recognized over the years that a high proportion of 
medulloblastoma survivors have significant long-term sequelae, mostly induced by 
craniospinal irradiation. Neurocognitive impairment occurs in a dose dependent manner and 
is more pronounced in children of younger age128. Other late side effects include hearing loss, 
growth and endocrinological deficits, gonadal dysfunction and secondary tumors129. 
 
                                                
iii
 Claudia C. Faria, Roberto J. Diaz and James T. Rutka (2014). Novel Therapies and Next Generation Clinical 
Trials in Medulloblastoma, Medulloblastoma Book, Dr. Dimitris Kombogiorgas (Ed.), Nova Science Publishers 
(in press). 
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Table 1.2: Clinical trials in medulloblastoma. 
Therapeutic 
Regimen 
Clinical 
Trial 
Number of MB 
patients Results Reference 
Standard-risk medulloblastoma 
CSI (36 Gy) + 
vincristine Phase II 
63  
(48 standard-risk) 
90% 5-year PFS 1994 127 
CSI (23.4 Gy)  + 
vincristine Phase III 379 81% 5-year EFS 2006 
130 
CSI (25 Gy) + 8 
drugs in one day + 
etoposide and 
carboplatin 
Phase II 136 
64.8% 5-year EFS 
73.8% OS 
2005 131 
CSI (23.4 Gy), high-
dose chemotherapy 
and SCR 
Phase II 
134  
(86 standard-risk) 
85% 5-year OS 
83% 5-year EFS 
2006 132 
Conformal 
radiotherapy 
Clinical 
study 86 83% 5-year EFS 2008 
133 
STRT vs HFRT Phase II 340 
STRT: 77% 5y EFS, 
87% 5y OS 
HFRT: 78% 5y EFS, 
85% 5y OS 
2012 134 
High-risk medulloblastoma 
CSI (36 Gy) + 
vincristine Phase II 63 (15 high-risk) 67% 5-year PFS 1994 
127 
8-in-1 chemotherapy 
or VCP + 
radiotherapy 
Phase III 
203  
(83 high-risk) 
40% 5-year PFS (M2) 
57% 5-year PFS (M1) 
1999 135 
Post-op neoadjuvant 
chemo vs immediate 
pot-op radiotherapy 
Phase II 
137  
(19 high-risk) 
66% 3-year PFS (all 
patients) 
30% 3-year PFS (M2/3) 
2000 136 
CSI (36-39.6 Gy), 
high-dose chemo 
and SCR 
Phase II 
134  
(48 high-risk) 
70% 5-year OS 
70% 5-year EFS 
2006 132 
Post-op neoadjuvant 
chemotherapy + CSI Phase III 68 
43.9% 5-year OS 
34.7% 5-year EFS 
2005 137 
Intensive sequential 
chemotherapy + 
HART 
Phase III 33 
72% 5-year PFS 
73% 5-year OS 
2009 138 
Topotecan + CSI + 
high-dose chemo + 
SCR 
Phase II 
53  
(19 high-risk) 
73.7% 2-year PFS 2001 139 
Induction chemo + 
single myeloablative 
cycle + SCR 
Phase II 21 48% 3-year PFS 60% 3-year OS 2004 
140 
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Recurrent medulloblastoma 
Thiotepa and 
etoposide + SCR Phase I 6 2 patients with PR 1996 
141 
Cyclophosphamide 
and melphalan + 
SCR 
Phase I 8 
1 patient with CR 
4 patients with PR 
1996 142 
Carboplatin, thiotepa 
and etoposide + SCR Phase I 23 
34% 3-year PFS 
46% 3-year OS 
1998 143 
Carboplatin, thiotepa 
and etoposide + SCR Phase II 25 
24% 10-year PFS and 
OS 2010 
144 
Busulfan and 
thiotepa + SCR Phase II 39 50-77% 5-year OS 2007 
145 
Temozolomide Phase II 25 
1 patient with CR 
2 patients with PR 
2007 146 
Temozolomide and 
etoposide (oral) Phase I 14 1 CR, 2 PR, 7 SD, 3 PD  2010 
147 
Etoposide (oral) Phase II 4 3 patients with PR 1997 148 
Etoposide, 
Cisplatinum and CSI Phase II 28 
57.6% 5-year PFS 
80% 5-year OS 
2012 149 
Irinotecan Phase II 3 2 patients with SD 2002 150 
Irinotecan Phase II 25 4 patients with PR 2007 151 
Irinotecan and 
carboplatin Phase I 2 
1 patient with CR 
1 patient with PR 
2009 152 
Irinotecan and 
temozolomide Phase II 66 33% objective response 2013 
153 
Medulloblastoma (MB); Craniospinal irradiation (CSI); Progression-free survival (PFS); Event-free survival 
(EFS); Overall survival (OS); Standard fractionated radiotherapy (STRT); Hyperfractionated radiotherapy 
(HFRT); Stem cell rescue (SCR); Vincristine, lomustine (CCNU) and prednisone (VCP); eight drugs in one day 
(8-in-1); M1: microscopic tumor cells in the cerebrospinal fluid; M2: gross nodular seeding in the cerebellum, 
cerebral subaracnoid space, or in the third or fourth ventricles; M3: gross nodular seeding in the spinal 
subaracnoid space; Hyperfractionated accelerated radiotherapy (HART); Stem cell rescue (SCR); Partial 
response (PR); Complete response (CR); Stable disease (SD); Progressive disease (PD)  
 
 
In order to reduce morbidity and improve the quality of life of patients with 
medulloblastoma, subsequent studies attempted to reduce the dose of craniospinal irradiation 
from 36 Gy to 23.4 Gy. This therapeutic approach reduced long-term neurocognitive deficits 
in children younger than 8 years154. A phase III study enrolled 421 patients with standard-risk 
medulloblastoma (379 patients were eligible). All patients received weekly vincristine 
concurrent with reduced-dose craniospinal irradiation, followed by a multidrug therapy with 
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cisplatin/vincristine/lomustine or cisplatin/vincristine/cyclophosphamide. The 5-year event-
free survival using this regimen was over 80% and the adjuvant chemotherapy did not 
influence outcome130. 
A study from the French Society of Pediatric Oncology included 136 patients with a 
standard-risk medulloblastoma and a median age of 8 years. The treatment included 8 drugs 
in one day followed by etoposide or carboplatin, both administered before radiotherapy. The 
overall survival rate was 73.8% and the event-free survival rate was 64.8%131.  
Another study used risk-adapted radiotherapy in 134 patients with medulloblastoma 
(86 standard-risk treated with 23.4 Gy and 48 high-risk treated with 36-39 Gy) followed by 
four cycles of high-dose chemotherapy and stem cell or bone marrow rescue. The reported 5-
year overall survival was 85% for standard risk patients and 70% in high-risk patients132. 
To limit the irradiated volume and the subsequent neurocognitive deficits, a protocol 
using conformal radiotherapy to the posterior fossa (36 Gy) and to the primary site (55.8 Gy) 
was used in 86 patients with standard-risk medulloblastoma. The irradiation to the primary 
site targeted the tumor surgical bed surrounded by a 2 cm margin. In this study, the control of 
the disease was comparable to that after radiation of the entire posterior fossa, with a 5-year 
event free survival of 83%133. 
A recent multicenter prospective randomized trial compared the event-free survival 
(EFS) and OS of 340 children treated with hyperfractionated radiotherapy (HFRT) and 
standard fractionated radiotherapy (STRT), followed by conventional chemotherapy. The 
survival rates did not differ significantly between the two therapeutic regimens, after a 
median follow up of 4.8 years. The reported 5-year EFS was 77% in the STRT group and 
78% in the HFRT group; the 5-year OS was 87% and 83%, respectively134. 
 
1.3.1.2 High-risk patients 
There is no standard chemotherapeutic regimen for patients with high-risk 
medulloblastoma. Despite high doses of radiation and intense adjuvant chemotherapy the 
prognosis of these patients is still very poor. Over the years, several clinical trials used 
different treatment schedules to achieve better control of the disease. 
The Children’s Cancer Group 921 phase III trial randomized high-risk 
medulloblastoma patients into an “eight-drugs-in-one” chemotherapy before and after 
radiotherapy or weekly vincristine during radiotherapy followed by vincristine, lomustine 
(CCNU) and prednisolone (VCP regimen). For the 83 metastatic patients with 3 years of age 
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or older, the 5-year progression-free survival (PFS) was significantly lower than the standard-
risk patients (70% M0; 57% M1; 40% M2)135. The German multicenter prospective trial 
HIT’91 compared post-operative neoadjuvant chemotherapy consisting of ifosfamide, 
etoposide, cysplatin, cytarabine and intravenous high-dose methotrexate, with immediate 
post-operative radiotherapy followed by maintenance chemotherapy with vincristine, 
cisplatin, and CCNU (“Philadelphia protocol”). The 3-year PFS rates were 66% for all 
randomized patients, 72% for patients without residual disease after surgery, 68% for patients 
with residual disease and 30% for patients with metastatic disease. Although neoadjuvant 
chemotherapy resulted in higher response rates and lower toxicity than maintenance 
chemotherapy, it induced an increased myelotoxicity of subsequent radiotherapy136. In the 
European phase III trial (PNET-3) M2/M3 stage medulloblastoma patients were treated with 
neoadjuvant chemotherapy (vincristine, carboplatin, etoposide and cyclophosphamide) 
followed by craniospinal irradiation (35 Gy). When compared with other multi-institutional 
series, the outcome for metastatic patients did not improve, with 5-year OS and EFS rates of 
43.9% and 34.7%, respectively137. 
More recently, a study including 33 patients with metastatic medulloblastoma used 
hyperfractionated accelerated radiotherapy (HART) (39 Gy craniospinal with a posterior 
fossa boost up to 60 Gy) after intensive sequential chemotherapy for 2 months. Patients 
showing persistent metastatic disease before HART were consolidated with two 
myeloablative courses of chemotherapy (tiothepa) followed by circulating progenitor cell 
administration. The 5-year PFS and OS was 72% and 73%, respectively138. Other studies have 
reported encouraging results with high-dose chemotherapy and autologous stem cell rescue. 
This procedure requires induction, harvesting and re-administration of autologous stem cells 
to medulloblastoma patients that have been treated with high-dose chemotherapy. The 
patient’s stem cells are mobilized with factors including granulocyte colony stimulating factor 
(G-CSF) or Plerixafor (AMD3100), collected from peripheral blood or bone marrow and re-
infused. Strother et al. enrolled 19 high-risk medulloblastoma patients for treatment with 
topotecan, followed by craniospinal irradiation (36 to 39.6 Gy) and four cycles of high-dose 
chemotherapy, each followed by stem cell rescue. The 2-year PFS rate was 73.7%139. In 
another study, 21 young patients (between 7 months old and 10 years old) with disseminated 
medulloblastoma were treated with intensified induction chemotherapy (vincristine, 
cyclophosphamide, etoposide and methotrexate) followed by a single myeloablative 
chemotherapy cycle and autologous stem cell infusion. Patients older than 6 years old or with 
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residual disease after induction chemotherapy received craniospinal irradiation with a boost to 
the tumor bed. The reported 3-year OS was 60% and the PFS was 49%140. 
In a recent phase I/II study including 81 patients (median age of 8.7 years old) with 
metastatic medulloblastoma, Jakacki et al. evaluated the role of carboplatin as radiosensitizer 
during craniospinal irradiation. The study showed that carboplatin is well tolerated and may 
improve survival in patients with high-risk medulloblastoma at presentation155. 
 
1.3.1.3 Recurrent medulloblastoma 
There is considerable ongoing debate about the best therapeutic approach for patients 
with recurrent or relapsed medulloblastoma. The outcome for patients with recurrent disease 
following previous craniospinal irradiation and who undergo retreatment with conventional 
therapy is less than 5%. Therefore, other therapeutic regimens have been extensively 
investigated to improve the outcome of these patients156,157.  
The first reports of patients with recurrent brain tumors salvaged with high-dose 
chemotherapy combined with autologous stem cell rescue were almost two decades ago141-143. 
These early series suggested that the best candidates for high-dose chemotherapy were 
patients with minimal residual disease141. One study including 8 patients with recurrent 
medulloblastoma showed significant improvement in survival after intensive chemotherapy 
and stem-cell rescue with an OS of 46% at 36 months post-treatment143. This study also 
suggested that patients previously treated with a combination of radiation and chemotherapy 
had a worse outcome than patients treated with previous chemotherapy only. Later, another 
study used the same regimen to treat 25 patients with recurrent medulloblastoma previously 
irradiated. The reported 10-year PFS and OS were both 24%144. 
In a multicenter study including 39 infants with local recurrence or progression of 
medulloblastoma, 70% of the patients could be salvaged by surgical resection followed by 
local irradiation and intensive chemotherapy with stem-cell rescue145. When infants had a 
metastatic relapse, 50% could be salvaged with high-dose chemotherapy and stem-cell rescue 
although the neurocognitive outcome was very poor158. Despite the fact that regimens with 
intensive chemotherapy and stem-cell rescue have greatly increased survival of patients with 
recurrent medulloblastoma, the rate of toxicity and mortality related to hepatic veno-oclusive 
disease, systemic infections and multi-organ failure were worrisome. This led investigators to 
design clinical trials using different therapeutic approaches. 
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Temozolomide is a well-known DNA damaging agent that effectively crosses the 
blood-brain barrier. Its efficacy is higher in patients with low levels of the DNA repair 
enzyme O6-methylguanine-DNA methyltransferase (MGMT). Temozolomide has been 
included, as a single agent or in combination with other drugs, in several clinical trials for 
recurrent medulloblastoma. A phase II study from the Children’s Oncology Group treated 113 
patients with recurrent central nervous system tumors with temozolomide administered as 
monthly 5-day courses, for up to 12 cycles. Among the 25 medulloblastoma patients treated, 
there was one complete response and two partial responses146. A recent pilot study treated 
patients with local recurrence of medulloblastoma with reirradiation and concomitant 
temozolomide, alone or in combination with other drugs, in a metronomic schedule. The 
results showed that temozolomide can be a radiosensitizer to radiotherapy159. 
The synergistic effect of temozolomide with other chemotherapeutic agents has also 
been investigated. Ruggiero et al. conducted a phase I trial in 14 children with progressive or 
relapsed medulloblastoma treated with temozolomide and etoposide, both administered orally. 
The results from this study revealed one complete response after 4 cycles, 2 partial responses 
after 1 cycle, 7 patients with stable disease and 3 patients with progressive disease147. 
Recently, Aguilera et al. reviewed 9 patients with recurrent medulloblastoma treated with 
bevacizumab, irinotecan, with or without temozolomide. This therapeutic regimen was well 
tolerated and the reported OS was 13 months. At 6 months, 55% of patients responded to 
treatment and three showed a complete response160. Another very recent phase II multicenter 
trial was conducted using a combination of temozolomide and irinotecan in pediatric patients 
with recurrent or refractory medulloblastoma. Although this therapeutic regimen was well 
tolerated, objective responses were only seen in 33% of patients. However, the combination 
of both drugs seemed to be more beneficial than previous reports using temozolomide or 
irinotecan as single agents153. 
Another option for patients with recurrent medulloblastoma is etoposide, a 
topoisomerase inhibitor. An early study including patients with relapsed medulloblastoma, 
previously treated with conventional therapy or that failed to respond to salvage therapy, 
showed benefit of oral etoposide148. Recently, a phase II trial of 28 adults with 
medulloblastoma evaluated the effect of etoposide and cis-platinum in combination with 
radiotherapy. The authors reported a PFS of 57.6% and an OS of 80%149. There are some 
reports of phase I/II trials in patients with refractory solid tumors, including some patients 
with medulloblastoma, that showed some efficacy of another topoisomerase inhibitor, 
irinotecan. In a phase II study including 22 patients with malignant brain tumors, two of three 
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patients with medulloblastoma treated with irinotecan showed disease stabilization150. 
Another phase II clinical trial with irinotecan (administered for 5 days and repeated every 
three weeks) involving 171 children with refractory solid tumors, reported a partial response 
in 4 patients with medulloblastoma151. A combination therapy of irinotecan and carboplatin 
was assessed in a phase I trial involving 28 patients with refractory tumors, including 2 
medulloblastoma patients. In these patients, one complete response and one partial response 
were observed152. 
Despite the large number of chemotherapeutic agents available to treat recurrent 
medulloblastoma the results from clinical trials show a very low success rate. This may be 
due to various factors including changes in the eligibility criteria for patient’s selection, the 
number of patients with medulloblastoma enrolled and tumor heterogeneity. It is anticipated 
that clinical trials taking into consideration the molecular subgroups of medulloblastoma, may 
lead to more promising results. 
 
1.3.2 Emerging Targeted Therapies in Medulloblastoma 
The most recent discoveries in the genomic landscape of medulloblastoma shed some 
light on possible novel targets for the treatment of this disease. Few clinical trials were 
undertaken using some of these targeted therapies. 
The hedgehog pathway is known to have an important role during development and is 
aberrantly activated in 30% of medulloblastomas22. Hedgehog signaling is mainly regulated 
through a cascade of inhibitory signals. Binding of the hedgehog ligands (Sonic, Indian or 
Desert Hedgehog) to the Patched transmembrane receptor (PTCH1) relieves PTCH1 
inhibition of the neighbouring Smoothened receptor (SMO). This leads to downstream 
activation of the cytoplasmic proteins GLI1 and GLI2, through an intermediate SUFU. 
Activated GLI1 and GLI2 then translocate to the nucleus and induce gene expression of 
regulators of the hedgehog pathway, including GLI1 and PTCH1. Due to the involvement of 
the hedgehog pathway in cancer, its pharmacological inhibition became an attractive tool to 
study antitumor activity and several compounds were developed. 
Vismodegib is a potent SMO inhibitor that acts by binding to the extracellular domain 
of the receptor and induces a marked inhibition of downstream signaling161. Vismodegib was 
effective inducing tumor regression in a patient with metastatic medulloblastoma refractory to 
multiple therapies162. These findings prompted the establishment of phase I and phase II 
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clinical trials, some of them ongoing. A phase I trial assessed the safety of vismodegib in 68 
patients with refractory solid tumors including 33 advanced basal cell carcinomas and one 
medulloblastoma163. One pitfall of vismodegib is the development of acquired resistance. The 
first identified mechanism of resistance was a missense mutation in the extracellular domain 
of SMO, which prevents the binding of vismodegib. The mutation occurs at the position 1697, 
predicted to change codon 473 from Asp to His (D473H)164. Another study reported various 
mechanisms of resistance to SMO inhibition using another Smoothened inhibitor, NVP-
LDE225. Despite initial tumor regression, resistance developed shortly afterwards with 
mutations of SMO, amplifications of GLI2 and up-regulation of PI3K signaling pathway165. 
Therefore, tumors with amplifications in genes that encode key proteins downstream of the 
SMO receptor may have an inherent resistance to SMO inhibitors.  
Other phase I/II trials using vismodegib to treat patients with recurrent or refractory 
medulloblastoma are in progress (see www.clinicaltrials.gov). A phase I/II trial to assess the 
efficacy of vismodegib in combination with temozolomide is recruiting patients with 
refractory medulloblastoma and concomitant activation of the Sonic Hedgehog pathway.  
The significant antitumor properties of vismodegib along with the minor side effects 
that were reported with its administration make this drug attractive for future combination 
therapies. However, for young children one major concern using SMO inhibitors are the 
potential permanent defects in bone development induced by these drugs166. Appropriate 
patient selection will be crucial when enrolling patients for treatment with SMO inhibitors.  
The Notch pathway has been implicated in the regulation and maintenance of normal 
neural stem cells. The activation of Notch signaling occurs upon binding of the Delta and 
Jagged ligands expressed in adjacent cells. This triggers proteolytic cleavage of the Notch 
receptor by ADAM family protease and gamma secretase with the subsequent release of the 
Notch intracellular domain. The intracellular domain translocates to the nucleus and activates 
transcription. Notch signaling dysregulation has been associated with several cancers 
including brain tumors (medulloblastoma, ependymoma and glioma)167. In medulloblastomas, 
Notch signaling seems to play a key role in the sonic hedgehog subtype168 and is, therefore, 
an attractive therapeutic target. 
MK-0752, a gamma secretase inhibitor, has been tested in phase I clinical trials. 
Fouladi et al. assessed the pharmacokinetics and toxicity of MK-0752 in 23 children with 
refractory or recurrent central nervous system tumors, including 4 medulloblastomas169. 
Another recent phase I trial enrolled 103 adult patients with advanced solid tumors. The 
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authors reported one complete response and 10 patients with stable disease among patients 
with malignant gliomas170. 
Finally, aberrant signaling via the EGFR family (also called ERBB receptors) has also 
been reported in brain tumors. High expression of EGFR has been associated with brainstem 
glioma and high expression of ERBB2 with medulloblastoma and ependymoma171,172. A 
phase I trial of children with refractory central nervous system tumors showed that lapatinib 
was well tolerated173. Later, a phase II study with lapatinib was conducted in 34 children with 
recurrent brain tumors (14 medulloblastomas, 10 ependymomas and 10 high-grade gliomas) 
but no objective responses were observed174. 
Several other molecular and pharmaceutical targets have been implicated in 
medulloblastoma pathogenesis. These include receptor tyrosine kinases, like cMET, PDGF, 
ERB and IGF1R, and some downstream effectors such as c-MYC, PI3K/AKT and STAT3. 
Preclinical studies were undertaken using human cells lines and mouse models of 
medulloblastoma. As the field moves forward and new drugs are being developed, it is 
anticipated that many more clinical trials will follow, taking into consideration the molecular 
biology of medulloblastomas. 
 
1.3.3 Conclusions and Future Perspectives 
The treatment of medulloblastoma has undergone tremendous change over the past 
several years. Advances in surgical techniques, radiation and chemotherapeutic protocols 
have significantly improved survival and quality of life of patients with medulloblastoma. 
However, the toxicity induced by therapy and the poor outcome of patients with recurrent or 
metastatic disease remains a challenge and warrants the development of new therapeutic 
avenues.  
The recent identification of medulloblastoma subgroups has profoundly changed the 
way we should deal with this disease. The knowledge that the different subgroups have 
distinct outcomes has important clinical implications and has launched a debate about 
subgroup-specific therapy. WNT medulloblastoma patients, known to have an exceedingly 
good outcome, are now considered for de-escalation of therapeutic intensity. On the other 
hand, Group 3 patients, which have a very poor outcome, clearly need more intensified 
therapies or novel pharmacological approaches.  
An overwhelming amount of data from whole genome and whole exome sequencing 
has been generated uncovering key pathways and genetic changes that are crucial for tumor 
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initiation and maintenance. DDX3X mutations in WNT tumors, PVT1-MYC fusion in Group 3 
tumors and SNCAIP tandem duplication in Group 4 tumors are some examples of novel 
genetic events recently described. Preclinical studies with human cell lines and mouse models 
of medulloblastoma are currently ongoing to validate these and other molecular targets. Thus 
far, few drugs targeting specific pathways or receptors have completed phase I or phase II 
clinical trials, namely vismodegib (an inhibitor of SMO in hedgehog signalling), MK-0752 
(an inhibitor of gamma secretase in Notch signalling) and lapatinib (an inhibitor of EGFR and 
ERBB2). However, their efficacy was limited when administered as single agents. Drug-
acquired resistance has been a problem both in preclinical and in some human studies 
highlighting the importance of combination therapies in future clinical trials. Taking into 
consideration the heterogeneity and complexity of medulloblastoma it is very unlikely that 
this disease can be cured with single agent therapy.  
Next generation clinical trials are making their way into the clinical arena. Meticulous 
patient selection, stratification based on molecular subgroup affiliation and the combination 
of conventional and targeted therapies are most likely the key to improve survival and quality 
of life of children with medulloblastoma. 
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1.4 Hypothesis and Aims  
The objective of our work was to investigate whether we could use the gene 
expression signatures of medulloblastoma to identify novel subgroup-specific targeted 
therapies, focusing in subsets of patients with the worst prognosis. The design of our study 
included two different approaches for drug discovery: 1) targeting a pathway previously 
identified as relevant in medulloblastoma and 2) using computational tools to identify small 
molecules with the ability to revert the oncogenic gene signatures of medulloblastoma 
subgroups. 
 
The HGF/cMET pathway is known to be involved in medulloblastoma pathogenesis. 
We aimed to determine the subgroup-specific role of cMET in medulloblastoma and its 
clinical relevance. Furthermore, we aimed to evaluate the in vitro and in vivo effect of small 
molecule inhibition in cMET signaling. Given the importance of cMET in the process of 
dissemination in human cancers and the lack of therapeutic options for patients with 
metastatic medulloblastoma, we hypothesized that cMET small molecule inhibition would 
impair tumor invasion and dissemination in mouse models of the disease. Since one of the 
principle concerns when evaluating new drugs to treat brain tumors is whether they cross the 
blood-brain barrier, we aimed to design a method, based on mass spectrometry technology, to 
detect and quantify drugs in the central nervous system.  
 
Group 3 medulloblastomas are characterized by overexpression or amplification of the 
oncogene MYC and have the worst outcome of all medulloblastoma subgroups. Since the 
development of small molecule inhibitors of MYC has had limited success, an alternative 
approach is to target basic cellular processes that drive the oncogenesis of Group 3 tumors. 
The C-MAP is a bioinformatic tool that allows rapid in silico assessment of molecules with 
the ability to modulate biological processes or diseases. Therefore, we decided to query the C-
MAP database using the gene expression profile of Group 3 medulloblastomas to identify 
novel small molecules with predicted efficacy against this aggressive tumor. Furthermore, we 
aimed to validate our findings by testing the best-ranked compounds against medulloblastoma 
cell lines and medulloblastoma mouse xenografts representative of Group 3 tumors. 
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Chapter 2  
cMET Inhibition as a Molecular Therapy for Metastatic SHH 
Medulloblastomaiv 
 
2.1 Introduction 
Medulloblastoma has a high tendency to disseminate through the cerebrospinal fluid 
to the brain and the spinal cord leptomeninges. Dissemination is a known factor of poor 
survival, and occurs in one third of the children at the time of diagnosis and in two thirds by 
the time of relapse. Affected children are treated with craniospinal radiation and high-dose 
chemotherapy but the majority of survivors suffer from severe neurocognitive deficits 
induced by the deleterious effects of treatment on the developing nervous system132. The 
discovery of novel and less toxic therapies has been hampered by the poor understanding of 
the mechanisms of dissemination, and by the failure to account for the genetic divergence 
between metastatic lesions and their matched primary tumor. Recent studies have shed light 
into the candidate genes that drive leptomeningeal dissemination in medulloblastoma175,176 
but therapies that target both the primary and the metastatic compartment have not been 
identified.  
The HGF/cMET pathway is essential for cell proliferation and migration during 
embryogenesis66 and, in the central nervous system, it plays a critical role in cerebellar 
development71. Aberrant cMET signaling is known to be involved in tumor growth and 
metastatic behavior of several human cancers38,42. The transmembrane receptor cMET is 
activated through phosphorylation of tyrosine residues upon binding of its ligand HGF. These 
tyrosines recruit a variety of cytoplasmic effector proteins, including GRB2, GAB1, SRC and 
PLC. Phosphorylation of GAB1 upon binding to cMET at the plasma membrane can trigger 
multiple downstream effector cascades including MAPK and PI3K/AKT that function in 
                                                
iv
 Bioinformatic analysis of medulloblastoma samples was performed by Adrian Dubuc and Marc Remke. 
Assistance with assays to assess cMET and PDGFRß signaling was obtained from Brian Golbourn, Roberto 
Diaz and Sameer Agnihotri. Amanda Luck helped with the genotyping of Ptch+/-/SB11/T2Onc mice. Assistance 
with active caspase assays was obtained from Samantha Olsen. HPLC-MS/MS analysis of brain and plasma 
samples was performed by Denis Raynaud and Michael Leadly. Leoneardo Ermini performed the MALDI-TOF 
imaging. Assistance for immunostaining of human tissue microarrays was obtained from Andrey Korshunov and 
Nesrin Sabha.The remainder of experiments described in this chapter were performed by the candidate. 
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various cellular processes including cell proliferation, cell survival, migration and invasion177. 
In medulloblastoma, cMET activation has been associated with tumor growth and anaplastic 
histology77. cMET signaling is deregulated in medulloblastoma through multiple, independent 
molecular mechanisms including epigenetic silencing of an upstream inhibitor SPINT234,178. 
The HGF/cMET axis cooperates with other important signaling pathways in 
medulloblastoma, namely MYC80, SHH84 and focal adhesion kinase (FAK)179, to promote 
tumor formation and growth. Previous studies have shown that cMET inhibition can 
effectively decrease medulloblastoma cell migration and invasion89. 
Foretinib is an orally available multikinase inhibitor that targets cMET with high 
affinity (IC50 = 0.4 nmol/L)111. Foretinib has demonstrated antitumor activity in preclinical 
models of different tumor types such as ovarian cancer180, pancreatic islet cancer181 and 
hepatocellular carcinoma182. Partial response in a subset of patients was observed in a phase I 
clinical trial investigating the pharmacokinetics and safety of foretinib in patients with 
advanced solid tumors183. These findings led to a phase II clinical trial that demonstrated an 
association between the presence of MET germline mutations and the response to foretinib184. 
Other clinical trials are currently ongoing to determine the efficacy of foretinib in various 
solid, non-central nervous system tumors. To date, the ability of foretinib to penetrate the 
brain is unknown. 
Foretinib also targets other tyrosine kinases with lower affinity, including the platelet 
derived growth factor receptor beta (PDGFRß) with an IC50 of 9.6 nmol/L. Interestingly, 
PDGFRß is known to be overexpressed in metastatic medulloblastoma185,186 and targeting the 
receptor reduces proliferation and migration of medulloblastoma cell lines187. Activation of 
PDGFRß occurs through a similar mechanism to cMET receptor activation in which ligand 
binding (PDGF-BB) induces receptor autophosphorylation and activates downstream 
signaling via MAPK and AKT188. 
Therefore, we sought to establish the subgroup-specific role of cMET and PDGFRß in 
medulloblastoma, and to test the efficacy of foretinib to cross the blood-brain barrier and to 
target those pathways, both in the primary and in the metastatic compartments. 
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2.2 Methods and Materials 
 
2.2.1 Tumor Material and Patient Characteristics 
All tissues and clinicopathological information were serially collected in accordance 
with Institutional Review Boards from contributing institutions. Nucleic acid extractions were 
carried out as previously described16.  
 
2.2.2 Expression Profiling and Molecular Subgrouping 
Expression of candidate genes was assessed using the R2 software (http://r2.amc.nl) in 
independent gene expression cohorts15,16,20,23,33,189-192. Expression of reported intermediates of 
MET signaling were visualized using heatmaps38. Associations between gene expression and 
subgroup affiliation were evaluated using one-way ANOVA. P-values < 0.05 were considered 
to be statistically significant. 
 
2.2.3 Analysis of Somatic Copy Number Alterations 
Somatic copy number alterations were assessed on the Affymetrix Single Nucleotide 
Polymorphism 6.0 array platform in 1,239 cases. Raw copy number estimates were obtained 
in dChip, followed by CBS segmentation in R as previously described23. 
 
2.2.4 Cell Lines and Animal Models 
Human medulloblastoma cell lines (Daoy, ONS76 and D425) were kindly provided by 
Dr. Annie Huang, Hospital for Sick Children, Toronto, Canada. All cell lines were 
authenticated and tested by PCR. Daoy-GFP/Luciferase cells were generated as described 
previously193. Athymic nude mice were obtained from the Charles River Laboratory. Ptch+/-
/SB11/T2Onc mice 175 were generously provided by Dr. Michael Taylor, Hospital for Sick 
Children, Toronto, Canada. 
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2.2.5 Cell Culture Assays for cMET and PDGFRß Signaling 
Foretinib was purchased from Selleck Chemicals, dissolved in DMSO (Sigma) and 
stored at -20ºC. To study the effect of foretinib in the cMET and PDGFRß pathways, 
medulloblastoma cells were serum starved for 24 hours in media with 0.1% (Daoy and 
ONS76) and 2% FBS (D425), pre-treated with increasing concentrations of foretinib or 1% 
v/v DMSO for 2 hours and stimulated with human recombinant HGF (20 ng/mL; Sigma-
Aldrich) for 20 minutes or human PDGF-BB (20 ng/mL; Cell Signaling) for 10 minutes.  
 
2.2.6 Migration and Invasion Assays 
The protocols for migration and invasion assays were as described previously 194. 
For the radial migration assays, 2,000 Daoy cells and 3,000 ONS76 cells per well 
were seeded through a cell sedimentation manifold (CSM Inc.) onto a 10 well Teflon-coated 
slides (CSM Inc.) previously coated with 0.1% BSA. After 24 hours of incubation at 37ºC, 
regular media was replaced by starved media (0.1% FBS) containing HGF (50 ng/mL) or 
PDGF-BB (50 ng/mL) in the presence or absence of foretinib. Cells were allowed to migrate 
for 24 hours and the radius of the migrating cells was measured and compared to the initial 
radius using a Leica Fluorescent Stereoscope (2.5X magnification). 
For the invasion assays, Matrigel Invasion Chambers (8 µm pore size; BD 
Biosciences) were hydrated for 2 hours with DMEM. Daoy and ONS76 cells 
(50,000/chamber) were plated in the top chamber with starved media (0.1% FBS) containing 
dilutions of foretinib. The bottom chamber was loaded with serum free media (0.1% FBS) or 
serum free media supplemented with HGF (50 ng/mL) or PDGF-BB (50 ng/mL) and 
foretinib. After incubation at 37ºC for 16 hours, non-invading cells were removed and cells 
invading through the porous membrane were stained with DAPI and photographed with an 
Axiovert 200M (Carl Zeiss) microscope. The number of cells per 6 random fields was 
determined (10X magnification) using Volocity software (Perkin Elmer). 
 
2.2.7 Immunoblotting 
Cell lysates were obtained using RIPA buffer (Sigma) containing protease inhibitors 
(F. Hoffman-La Roche AG), 0.2 M sodium fluoride, 0.2 M sodium pyrophosphate and 0.2 M 
sodium orthovanadate. Protein concentration was determined using the Pierce BCA Protein 
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Assay Kit (Thermo Scientific). Proteins were electrophoresed on 7%, 7.5% or 10% SDS-
PAGE gels, depending on the protein that was being detected, and transferred using a semidry 
transfer apparatus (Bio-Rad). The following antibodies were used: cMET (1:1,000; L41G3, 
Cell Signaling), phospho-cMET (1:1,000; Tyr1234/1235, Cell Signaling), PDGFRß (1:500; 
28E1, Cell Signaling), phospho-PDGFRß (1:500; Tyr751, Cell Signaling), AKT (1:1,000; 
Cell Signaling), phospho-AKT (1:2,000; Ser473, Cell Signaling), p44/42 MAPK (1:1,000; 
Cell Signaling), phospho-p44/42 MAPK (1:2,000; Thr202/Tyr204, Cell Signaling), PARP 
(1:1,000; Cell Signaling), ß-actin (1:10,000; Cell Signaling), anti-rabbit IgG conjugated to 
horseradish peroxidase (1:5,000; Cell Signaling) and anti-mouse IgG conjugated to 
horseradish peroxidase (1:5,000; Amersham Biosciences). Western blot analysis and 
quantification was performed using the Fluorchem Q Imaging System (ProteinSimple). 
 
2.2.8 Cell Proliferation Assays 
Daoy, ONS76 and D425 cells were seeded in 96-well microplates at 2,500, 2,500 and 
10,000 cells per well, respectively. These cells were treated with different concentrations of 
foretinib or DMSO and cell viability was determined for the indicated time points by MTS (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) 
absorbance at 490 nm (CellTiter 96 Aqueous One Solution Reagent; Promega). Three 
independent experiments were performed with 16 repeats per treatment condition and per 
time point.  
 
2.2.9 Active Caspase Assays 
Daoy cells were seeded at 2,500 cells in 96-well microplates in the presence or 
absence of different concentrations of foretinib. The activity of caspases 3 and 7 was 
measured using the Apo-One® Homogeneous Caspase 3/7 assay (Promega). For the indicated 
time points, 100 µl of Apo-One solution was added to each well and the levels of 
fluorescence were measured after 12 hours of incubation. 
 
2.2.10 Foretinib Pharmacokinetic Studies 
Detection and quantification of foretinib was performed using a high-performance 
liquid chromatography tandem mass spectrometry (LC/MS/MS) method (Agilent 1290 HPLC 
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Agilent Technologies, Santa Clara, California, USA / QTRAP 5500 AB SCIEX, 
Framingham, Massachusetts, USA), with cabozantinib (Selleck Chemicals) as internal 
standard for brain homogenates and plasma. 
Images of foretinib distribution in various mouse organs were acquired using a matrix-
assisted laser desorption/ionization (MALDI) time-of-flight tandem mass spectrometer (AB 
SCIEX TOF/TOF 5800 System, AB SCIEX, Framingham, MA, U.S.A.). 
Female 5-6 week old athymic nude mice (Charles River) were dosed with 30, 60 and 
100 mg/kg of foretinib, by oral gavage. Mouse brains and matched blood samples were 
collected from animals (n = 3 per time point) at 5 hours, 10 hours and 5 days (after daily drug 
administration). Blood samples were collected by cardiac puncture into tubes containing 
EDTA and plasma was harvested by centrifugation at 800 x g for 15 minutes and stored at -
80ºC. Animals were perfused with saline containing heparin (5U/mL) and brains were 
harvested, frozen in liquid nitrogen and stored at -80ºC. High-performance liquid 
chromatography tandem mass spectrometry (LC/MS/MS) was used to detect and quantify 
foretinib (Agilent 1290 HPLC Agilent Technologies, Santa Clara, California, USA / QTRAP 
5500 AB SCIEX, Framingham, Massachusetts, USA). Cabozantinib (Selleck Chemicals) was 
used as internal standard for brain homogenates and plasma. At least 5 standards were run for 
each curve and the lower limit of quantitation (LLOQ) was 0.1 ng/mL. Foretinib 
concentration in whole brain was normalized by brain weight. 
For matrix-assisted laser desorption/ionization with time-of-flight mass spectrometer 
(MALDI-TOF) imaging, brain, liver and kidney from foretinib treated and untreated mice 
were frozen rapidly in liquid nitrogen and stored at -80°C. Samples were mounted with 
optimal cutting temperature (OCT) compound (Sakura Finetek, Torrance, CA) for sectioning. 
Tissues were cut in 12 μm sections at -15°C and mounted onto indium tin oxide (ITO)-coated 
glass slides. A thin matrix layer of 2,5-dihydroxybenzoic acid (DHB) was applied to the 
sections using an automated MALDI plate matrix deposition system (TM-Sprayer™, Leap 
Technologies, Carrboro, NC). A total of 5 mL of DHB solution (15 mg/mL in 50% 
acetonitrile/0.1% trifluoroacetic acid) was sprayed per slide during 4 passes at 140°C with a 
velocity of 400 mm/min and a line spacing of 3 mm. Images were acquired using a MALDI 
time-of-flight tandem mass spectrometer (AB SCIEX TOF/TOF 5800 System, AB SCIEX, 
Framingham, MA, U.S.A.). MALDI mass spectra were obtained using an Nd:YAG laser (349 
nm) at 3 ns pulse width and 400 Hz firing rate. All data were acquired in the positive-ion 
reflector mode. An aliquot of pure Foretinib (Selleck Chemicals) was deposited on the ITO-
coated slides as external standard and to compensate for mass shift. A total of 200 laser shots 
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per pixel were acquired (1 s/pixel) at a spacing of 100 mm between pixels. The mass 
spectrometric data was processed and images were visualized using TissueView software (AB 
SCIEX). The imaging experiments were repeated with tissues obtained from 3 animals treated 
and untreated with foretinib. 
 
2.2.11 Medulloblastoma Xenografts and Transgenic Mouse Models 
All mouse studies were approved and performed in accordance to the policies and 
regulations of the Institutional Animal Care and Use Committee of the University of Toronto 
and the Hospital for Sick Children, in Toronto. 
Mouse subcutaneous xenografts (Daoy and ONS76) were established in athymic nude 
mice (Charles River Laboratories). Foretinib was given orally, every other day, for 9 days at 
60 and 100 mg/kg. Intracranial xenografts of disseminated medulloblastoma were established 
by injecting Daoy medulloblastoma tumor cells into the fourth ventricle of athymic nude 
mice. Tumor growth and the presence of metastases were evaluated by weekly 
bioluminescence imaging using the IVIS Spectrum Optical In-vivo Imaging System (Caliper 
Life Sciences). Foretinib was administered daily by oral gavage, 6 days a week, for 2 weeks. 
Osmotic pumps (Alzet, model 2004) were implanted in Ptch+/- mice with Sleeping 
Beauty (SB) transposition (Ptch+/-/SB11/T2Onc) at post-natal day 30 to 35. Pumps loaded 
with foretinib (6 mg/kg) infused the drug into the cerebrospinal fluid (right lateral ventricle) 
for 28 days at a rate of 0.25 µl/hour. 
Female 5-6 week old athymic nude mice (Charles River Laboratories) were used for 
flank and intracranial xenografts. Daoy (2 x 106) and ONS-76 (2.5 x 106) were injected in the 
right flank of animals as a 1:1 suspension in Matrigel (BD Biosciences). At day 16 (Daoy) 
and day 13 (ONS76) after cell inoculation animals were randomized to a vehicle or drug 
treatment group. Foretinib was administered by oral gavage at 60 and 100 mg/kg, every other 
day for 9 days. Tumor volume was assessed using a digital caliper and the formula: tumor 
volume = length (mm) x width2 (mm2)/2. Tumors were excised at day 25 (Daoy) and day 21 
(ONS76) post-injection. 
For the intracranial xenografts of disseminated medulloblastoma, 5 x 105 Daoy 
GFP/Luciferase cells were injected into the fourth ventricle of nude mice using a stereotactic 
frame. Three days after cell inoculation bioluminescence imaging was conducted using the 
IVIS Spectrum Optical In-vivo Imaging System (Caliper Life Sciences).  Animals that had a 
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detectable signal were randomized to a foretinib (n = 11) or a DMSO (n = 11) treatment. 
Foretinib at 60 mg/kg was given orally once daily, 6 days a week, for 2 weeks. Tumor growth 
and dissemination were assessed by weekly bioluminescence imaging (BLI). Animals were 
euthanized upon signs of sickness or loss of weight greater than 20%. Brains and spinal cords 
of all animals were harvested and fixed in 10% formalin. Three serial sections of the brain 
and multiple sections of the cervical, thoracic and lumbar spinal cord (minimum of 30 
sections per spinal cord region) were analyzed. 
  We used Ptch+/- mice with Sleeping Beauty (SB) transposition (Ptch+/-/SB11/T2Onc) 
as a spontaneous mouse model of metastatic medulloblastoma. Osmotic pumps (Alzet, model 
2004) were implanted in animals at post-natal day 30 to 35 and brain infusion cannulas were 
placed in the right lateral ventricle. Pumps were previously loaded with 6 mg/kg of foretinib 
and infused the drug for 28 days at a rate of 0.25 µl/hour. Mouse brains and spinal cords were 
harvested and sectioned as described above.  
 
2.2.12 Immunohistochemistry  
The protocol for immunohistochemistry was performed as previously described195. 
The following antibodies were used: Ki-67 (1:1,000; Novus), cleaved caspase 3 (1:800; Cell 
Signaling), phospho-cMET (1:100; Tyr1234/1235, Cell Signaling) and phospho-PDGFRß 
(1:200; Tyr751, Abcam). For immunohistochemical quantification, four 20X magnification 
fields per tumor were used and a total number of 3 mice per group were assessed. 
 
2.2.13 Statistical Analysis 
Survival curves according to p-cMET status were generated using the Kaplan-Meier 
estimate and a log-rank test.  The comparison between binary and categorical patient 
characteristics was performed using the two-sided Fisher’s exact test. To analyze contiguous 
variables, the Mann-Whitney U test was used.  
Results from experiments were expressed as mean ± SEM. For multiple group 
comparisons, analysis of variance (ANOVA) was conducted followed by a post-Tukey test (to 
identify differences among sub-groups) or a post-Dunnetts test (to compare groups to one 
control group). Direct comparisons using an unpaired two-tailed Student’s t-test were 
conducted where appropriate. Statistical analysis was performed using GraphPad Prism 5 
Software. We considered a P-value inferior to 0.05 as significant.  
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2.3 Results 
 
2.3.1 cMET and PDGFRß are Highly Expressed in SHH 
Medulloblastomas 
We evaluated the expression of cMET and PDGFRß in a discovery cohort of primary 
medulloblastomas from Boston (n = 199)191. cMET expression was highly upregulated in 
most SHH medulloblastomas and in a subset of Group 3 tumors (Figure 2.1A). PDGFRß was 
expressed across all medulloblastoma subgroups, with higher levels of expression in SHH 
tumors (Figure 2.1B). We confirmed our results using a multicentre validation cohort of 439 
cases profiled on the Affymetrix 133plus 2.0 arrays obtained from the German Cancer 
Research Centre, Heidelberg (validation cohort 1)20,189,190,192(Figures 2.1C and 2.1D).  
 
Figure 2. 1: cMET and PDGFRß expression accross medulloblastoma subgroups.  
Expression of (A) cMET (P < 0.0001) and (B) PDGFRß (P < 0.01) mRNA in a discovery 
cohort of primary medulloblastomas (Boston; n = 199). cMET (C) (P < 0.0001) and PDGFRß 
(D) (P < 0.0001) expression analysis in a validation cohort with 439 cases (validation cohort 
1: multicentre cohort obtained from Heidelberg). 
B D
A  Discovery cohort (n=199) C  Validation cohort 1 (n=439)
cM
ET
 e
xp
re
ss
ion
0
100
200
300
400
500
600
700
800
WNT SHH Group 3 Group 4Adult CB
cM
ET
 e
xp
re
ss
ion
0
200
400
800
1000
1200
0
20
40
60
80
100
120
140
160
180
PD
GF
Rß
 e
xp
re
ss
ion
 Discovery cohort (n=199)
0
50
100
150
200
250
300
350
400
PD
GF
Rß
 e
xp
re
ss
ion
 Validation cohort 1 (n=439)
P<0.0001 P<0.0001
P<0.01 P<0.0001
600
WNT SHH Group 3 Group 4 Fetal
CB
Adult
CB
WNT SHH Group 3 Group 4Adult CB WNT SHH Group 3 Group 4 Fetal
CB
Adult
CB
Using Genomics for Drug Discovery in Medulloblastoma 
 76 
To identify molecular markers of cMET pathway activation in SHH 
medulloblastomas, we interrogated three independent datasets (discovery cohort from Boston; 
validation cohort 1 from the German Cancer Research Centre, Heidelberg; and validation 
cohort 2: multicentre cohort from the Medulloblastoma Advanced Genomics International 
Consortium - MAGIC) using a group of genes known to activate cMET signaling38,177. In 
addition to cMET, GAB1 expression was highly and specifically up-regulated in SHH-driven 
medulloblastomas, across the three non-overlapping cohorts, when compared to normal 
cerebellum and to non-SHH medulloblastomas (Figures 2.2A–F). 
To investigate possible mechanisms leading to cMET and PDGFRß overexpression, 
we examined the subgroup-specific CNAs encompassing the MET loci (7q31.2) and the 
PDGFRß loci (5q31), in a large cohort of 1,239 medulloblastomas23. There were no focal 
gains or amplifications of cMET (Figure 2.3A) and very infrequent copy number gains 
affecting the PDGFRß loci (Figure 2.3B). 
 
2.3.2 Identification of Biological Pathways and Processes Associated 
with High cMET and Low cMET SHH Medulloblastomas 
To identify signaling pathways and biological processes discriminating high cMET 
and low cMET SHH medulloblastomas we performed Gene Set Enrichment Analysis between 
tumors with the highest (n = 13) and the lowest (n = 13) cMET expression across a series of 
51 primary SHH medulloblastomas23. Gene sets were compiled from Gene Ontology (GO), 
Kyoto Encyclopedia of Genes and Genomes (KEGG), the National Cancer Institute (NCI), 
Protein Families (PFAM) and Biocarta pathway databases. To visualize significant gene sets 
(FDR < 0.25; P < 0.01) as interaction networks we used Cytoscape and Enrichment Map 
(Figure 2.4). High cMET SHH medulloblastomas were characterized by gene sets involved 
in organ development and morphogenesis, cell migration (cell motility and extracellular 
matrix components), cell cycle and DNA repair, T-cell differentiation, transcription 
(transcription factor activity, RNA processing, nuclear and RNA transport) and mitochondrial 
function. Low cMET SHH medulloblastomas were defined by numerous networks including 
neural development (neurogenesis, cell morphogenesis and polarity), neurotransmission 
(neurotransmitter release and activity, ion transport, calcium signaling, chemical homeostasis, 
cytoplasmic vesicle formation), amino acid and nucleotide metabolism, ribonucleotide 
biosynthesis, smooth muscle contraction and Ras-GTPase activity. 
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Figure 2.2: cMET as a signature gene in SHH medulloblastoma. 
(A – C), heatmaps illustrating aberrant overexpression of cMET activators in SHH 
medulloblastomas, in three non-overlapping cohorts of patients, (A) discovery cohort 
(Boston; n=199), (B) validation cohort 1 (multicentre cohort obtained from Heidelberg; 
n=439) and (C) validation cohort 2 (Medulloblastoma Advanced Genomics International 
Consortium – MAGIC; n=285). (D – F), Z-scores demonstrating cMET activation in SHH 
tumors when compared to other medulloblastoma subgroups and normal cerebellum (CB), in 
all datasets (*P < 0.05; ***P < 0.001). 
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Figure 2.3: Subgroup-specific copy number aberrations in primary medulloblastomas. 
Copy number aberrations in (A) the MET loci (7q31.2) and in (B) the PDGFRß loci (5q31). 
Molecular subgroups: WNT (blue), SHH (red), Group 3 (yellow) and Group 4 (green). 
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Figure 2.4: Biological pathways and processes associated with high cMET and low cMET 
SHH medulloblastomas. 
Gene Set Enrichment Analysis (GSEA) comparing high cMET (red) against low cMET (blue) 
SHH medulloblastomas and identifying distinct pathways and biological processes between 
both subgroups (FDR < 0.25; P < 0.01). For visualization of the GSEA results, Cytoscape and 
Enrichment Map were used. The enriched gene sets were represented as nodes, grouped by 
their similarity, and mapped as a network. The total number of genes within each gene set 
determines the size of the node. 
 
2.3.3 High p-cMET Levels Correlate with Recurrence and Poorer 
Survival in SHH Medulloblastomas  
To evaluate the clinical significance of cMET, we stained medulloblastoma tissue 
microarrays (TMA) comprised of an independent cohort of 385 patients, for the activated 
cMET receptor or phosphorylated cMET (p-cMET). Eighty percent (104/128) of SHH tumors 
and approximately 25% (16/62) of Group 3 tumors showed high p-cMET staining (Figure 
2.5A). Interestingly, there was a significant correlation (P = 0.041) between high p-cMET and 
Cell Motility Cell Cycle DNA Repair
Extracellular Matrix 
Components
cMet Signaling
T-Cell Di!erentiation
Transcription Factor Activity
RNA processing
Transcription
RNA Transport
Mitochondrial FunctionNuclear Transport
Organ Development and Morphogenesis
Amino Acid Metabolism
Ion Transport
Ribonucleotide 
Biosynthesis
Nucleotide 
Metabolism
Neurotransmitter
Release
Cell Morphogenesis 
and Polarity
Smooth Muscle Contraction
Ras-GTPase Activity
Neurogenesis
Chemical
Homeostasis
Neurotransmitter 
Activity
Cytoplasmic Vesicle Formation
Calcium Signaling
High cMET
Low cMET
Shared Genes
P < 0.01
FDR < 0.25
Using Genomics for Drug Discovery in Medulloblastoma 
 80 
an increased 5-year rate of recurrence across all subgroups of pediatric medulloblastomas 
(Figure 2.5B). These trends were most pronounced (P = 0.011) across pediatric SHH tumors 
(Figure 2.5C). 
 
Figure 2.5: cMET pathway activation as a hallmark of SHH medulloblastomas.  
(A) Immunopositivity for activated cMET (phosphorylated cMET or p-cMET) is a hallmark 
feature of SHH medulloblastomas identified by immunohistochemistry of medulloblastoma 
tissue microarrays in a cohort of 385 patients. Representative photographs of tumors with 
high p-cMET and low p-cMET staining are shown. Scale bar: 100 µm. (C and D) In pediatric 
medulloblastomas, high p-cMET correlates with an increased 5-year recurrence rate (B) 
across all subgroups (P = 0.041) and particularly, in (C) the SHH subgroup (P = 0.011). 
 
High p-cMET across medulloblastoma subgroups was associated with older age at 
diagnosis (Figures 2.6A and 2.6B) and desmoplastic histology (Figures 2.6C and 2.6D), 
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association of p-cMET expression and the presence of metastases or TP53 mutational status 
in SHH tumors (Figures 2.6E and 2.6F). 
  
Figure 2.6: Clinicopathological correlations of SHH medulloblastomas according to p-cMET 
status.  
(A and B) Box plots demonstrating the association of p-cMET expression and age (A) across 
medulloblastoma subgroups and (B) within the SHH subgroup. Statistical significance was 
determined by a Mann-Whitney U test. (C and D) Distribution of histological variants across 
(C) all medulloblastoma subgroups and (D) SHH subgroup. P-values were determined by 
Fisher’s exact test. (E and F) Association of p-cMET expression in SHH medulloblastomas 
with (E) metastatic status and (F) TP53 mutational status. Statistical significance was 
calculated by Fisher’s exact test.  
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A striking association between p-cMET expression and outcome was noted in SHH 
medulloblastomas. Specifically, high p-cMET expression in SHH tumors was associated with 
a significantly (P = 0.007) shorter progression-free survival (Figure 2.7A), particularly in the 
pediatric cohort (P = 0.002) (Figure 2.7B). A trend toward a worse overall survival was also 
observed in these patients (Figures 2.7C and 2.7D).  
 
 
Figure 2.7: cMET pathway activation identifies subgroups of SHH medulloblastoma with 
distinct clinical outcomes.  
(A – D) Kaplan-Meier survival curves demonstrate that SHH medulloblastomas with high p-
cMET have a poorer progression-free survival, particularly within the pediatric cohort. 
Statistical significance of recurrence was determined by a Fisher’s exact test and survival by a 
log-rank test. PFS, progression-free survival; OS, overall survival. 
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Interestingly, considering the metastatic status within SHH medulloblastomas, the 
prognostic impact of high p-cMET expression was still observed. High p-cMET correlated (P 
= 0.022) with a poor outcome in non-metastatic SHH patients (Figures 2.8A and 2.8B). A 
trend toward a worse survival was observed in patients with high p-cMET and leptomeningeal 
dissemination at diagnosis (Figures 2.8C and 2.8D).  
 
Figure 2.8: Prognostic impact of leptomeningeal dissemination according to p-cMET status 
in SHH medulloblastomas. 
Kaplan-Meier survival curves displaying progression-free survival and overall survival 
according to p-cMET status in (A and B) non-metastatic SHH medulloblastomas (M0) and 
(C and D) metastatic SHH medulloblastomas (M+) across all ages. Statistical significance of 
recurrence was determined by a Fisher’s exact test and survival by a log-rank test. PFS, 
progression-free survival; OS, overall survival. 
 
Survival differences could not be determined in adult SHH medulloblastoma patients 
according to p-cMET status (Figures 2.9A and 2.9B). In Group 3 medulloblastomas, 
expression of p-cMET had no prognostic relevance and did not correlate with metastatic 
status. 
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 Thus, we conclude that activated cMET defines distinct prognostic patient cohorts 
with higher recurrence rate and poorer prognosis in SHH subgroup of medulloblastomas. 
 
 
Figure 2.9: Prognostic impact of p-cMET status in adult SHH medulloblastomas. 
Kaplan-Meier survival curves displaying (A) progression-free survival (PFS) and (B) overall 
survival (OS) according to p-cMET status in adult SHH medulloblastomas. Statistical 
significance of recurrence was determined by a Fisher’s exact test and survival by a log-rank 
test. 
 
2.3.4 Foretinib Inhibits cMET and PDGFRß Pathway Activity  
Based on the elevated expression levels of cMET and PDGFRß in SHH and Group 3 
medulloblastomas we sought to evaluate the antitumoral effect of foretinib against 
medulloblastoma cell lines representative of these two subgroups. Daoy, ONS76 and D425 
human medulloblastoma cell lines have transcriptional and cytogenetic features that suggest 
they are originally derived from SHH (Daoy and ONS76) and Group 3 (D425) tumors196. 
Furthermore, they express different levels of the tyrosine kinase receptors cMET and 
PDGFRß (Figure 2.10A). First, we evaluated the ability of foretinib to inhibit the cMET and 
the PDGFRß pathway activity in the context of HGF or PDGF-BB stimulation. Foretinib 
potently inhibited the HGF-induced cMET pathway activation, as evidenced by the 
suppression in cMET phosphorylation (P < 0.01) and also by the decrease in the 
phosphorylation of downstream effectors AKT and MAPK (Figures 2.10B and 2.10C). The 
inhibitory effect of foretinib in PDGF-BB-induced PDGFRß pathway activation resulted in 
inhibition of PDGFRß phosphorylation and only moderate inhibition of downstream signaling 
(Figures 2.11A and 2.11B).  
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Figure 2.10: cMET pathway targeting by foretinib in human medulloblastoma cell lines.  
(A) Western blot of cMET and PDGFRß expression in several medulloblastoma cell lines 
showing variable expression levels. (B) Daoy and (C) ONS76 cells were serum starved for 24 
hours, pre-treated with different concentrations of foretinib and stimulated with HGF (20 
ng/mL). The phosphorylation levels of cMET, AKT and MAPK were determined using 
Western blot and chemoluminescence densitometric analysis. Fold change in densitometric 
analysis represents the phosphorylated proteins compared to total proteins. Data represent 
mean of triplicates ± SEM (*P < 0.05; **P < 0.01). 
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Figure 2.11: PDGFRß pathway inhibition by foretinib in human medulloblastoma cell lines. 
Serum starved (A) Daoy and (B) D425 medulloblastoma cells were pre-treated with foretinib 
for 2 hours and stimulated PDGF-BB (20 ng/mL). Inhibition of PDGFRß pathway and 
downstream signaling were determined by Western blot and chemoluminescence 
densitometric analysis. Fold change in densitometric analysis represents the phosphorylated 
proteins compared to total proteins. Data represent mean of triplicates ± SEM (*P < 0.05). 
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Furthermore, a significant (P < 0.001) anti-proliferative effect was observed in 
foretinib treated Daoy, ONS76 and D425 medulloblastoma cells (Figures 2.12A – C). The 
reduction in cell proliferation was matched by an induction of apoptosis as shown by the 
increase in PARP cleavage (Figures 2.12D – F) and in caspase 3 and 7 activity (Figures 
2.12G and 2.12H).  
 
Figure 2.12: Anti-proliferative and pro-apoptotic effects of foretinib in human 
medulloblastoma cells. 
Viability of  (A) Daoy, (B) ONS76 and (C) D425 cells treated with varying concentrations of 
foretinib and measured over 96 hours by MTS assay. Data represent mean of triplicates ± 
SEM (***P < 0.001). (D – F) Western blot showing PARP and cleaved PARP antibodies 
probing cell lysates from Daoy, ONS76 and D425 cells treated with foretinib for different 
time points. (G and H) Cleaved caspase 3/7 assays demonstrating induction of apoptosis after 
foretinib treatment in Daoy and ONS76 cells. RFU: Relative Fluorescence Units. Data 
represent mean of triplicates ± SEM (***P < 0.001). 
0 24 48 72 96
0.0
0.2
0.4
0.6
0.8
1.0 Control
500 nM     
1 +M
2.5 +M
Time (h)
Ab
so
rb
an
ce
 (4
90
 n
m
)
***
B
0 24 48 72 96
0.0
0.2
0.4
0.6
0.8 Control
1 +M
2.5 +M
5 +M
Time (h)
Ab
so
rb
an
ce
 (4
90
 n
m
)
***
E
PARP
Cleaved PARP
ћ$FWLQ
Foretinib 10 µM -
Co
nt
ro
l
- - -+ + +
6h 12h 24h
C F
ONS76
D425
ONS76
Foretinib 1 µM -
Co
nt
ro
l
- - -+ + +
24h 48h 72h
PARP
Cleaved PARP
ћ$FWLQ
D425
0 24 48 72 96
0.2
0.4
0.6 Control
500 nM     
1 +M
2.5 +M
0
Time (h)
Ab
so
rb
an
ce
 (4
90
 n
m
)
***
A D
Foretinib 1 µM -
Co
nt
ro
l
- - -+ + +
24h 48h 72h
PARP
Cleaved PARP
ћ$FWLQ
24 48 72 
0
3000
6000
9000
12000
!"#$%"&
'"%($)#)*+,++-
Time (h)
Ca
sp
as
e 
3/
7 
ac
tiv
ity
 (R
FU
)
***
***
Daoy
6 12 24 
0
100
200
300
400 !"#$%"&
'"%($)#)*+,.++-
Time (h)
Ca
sp
as
e 3
/7 
ac
tiv
ity
 (R
FU
)
***
Daoy
G
H
Daoy
ONS76
Using Genomics for Drug Discovery in Medulloblastoma 
 88 
 
Foretinib potently inhibited HGF-mediated migration (Figures 2.13A – 2.13D) and 
invasion (Figures 2.14A and 2.14B) of Daoy and ONS76 cells for all drug concentrations. In 
contrast, a significant reduction in migration and invasion mediated by PDGF-BB was only 
seen with 2.5 µM of foretinib (Figures 2.13E and 2.14C). Collectively, these results suggest 
that foretinib exhibits a significant in vitro inhibitory activity in medulloblastoma cells, 
mainly through blockade of the cMET pathway. 
 
 
 
Figure 2.13: Effect of cMET and PDGFRß inhibition in medulloblastoma migration. 
Representative images of radial migration assays with (A) Daoy and (B) ONS76 cells under 
HGF stimulation (2.5X magnification). Foretinib inhibits (C and D) HGF and (E) PDGF-BB-
dependent cell migration. Data represent mean of triplicates ± SEM (*P < 0.05; **P < 0.01).  
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Figure 2.14: Effect of cMET and PDGFRß inhibition in medulloblastoma invasion. 
Foretinib reduces (A and B) HGF and (C) PDGF-BB-dependent medulloblastoma cell 
invasion. Representative photographs are shown with the nuclei stained with DAPI. The 
number of cells per 6 random fields was determined (10X magnification). Data represent 
mean of triplicates ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001). 
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2.3.5 Foretinib Induces Medulloblastoma Regression In Vivo 
Having assessed the efficacy of foretinib in vitro, we sought to investigate its 
antitumor activity in vivo using subcutaneous xenograft models of SHH medulloblastoma. 
Daoy and ONS76 cells were implanted in the flank of nude mice and animals with established 
tumors were treated by oral gavage with vehicle (DMSO) or foretinib (60 and 100 mg/kg), 
once every other day for 9 days. Therapy with foretinib significantly induced tumor 
regression at all drug concentrations administered. At the end of treatment, tumor volumes 
were reduced by 37% and 46% with 60 and 100 mg/kg of foretinib, respectively, in Daoy 
xenografts (Figures 2.15A and 2.15B) and by 50% in ONS76 xenografts (Figures 2.16A 
and 2.16B). Foretinib was well tolerated as mice body weights were maintained during the 
treatment period for all cohorts (Figures 2.15C and 2.16C). 
 Medulloblastoma tumor growth inhibition in mice treated with foretinib was 
associated with concomitant reduction in cMET and PDGFRß pathway activity (Figures 
2.15D and 2.16D). Compared to tumors treated with vehicle, foretinib treatment resulted in a 
potent inhibition of cMET phosphorylation in all cohorts (Figures 2.15E and 2.16E) and a 
moderate reduction in PDGFRß activation (Figure 2.15F). Tumors treated with foretinib also 
displayed significant dose-dependent decrease in cell proliferation (Figures 2.15G and 
2.16F), and increase in apoptosis (Figures 2.15H and 2.16G). 
 These studies demonstrate that foretinib has a significant in vivo antitumor effect in 
medulloblastoma allografts, through a potent suppression of the cMET pathway activity and a 
moderate inhibition of PDGFRß signaling. 
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Figure 2.15: Foretinib induces regression of Daoy medulloblastoma flank xenografts. 
Nude mice with Daoy hindflank xenografts were treated with vehicle control (10% DMSO, n 
= 6) or foretinib (60 and 100 mg/kg; n = 6 per group), once every other day for 9 days. Effect 
of foretinib on tumor growth was compared during treatment (A) and in the end of treatment 
(B). Data represent group means ± SEM (***P < 0.001). (C) Average animal body weight 
before and after therapy. (D) Flank tumors treated with foretinib show inhibition of p-cMET 
and p-PDGFRß, decreased cell proliferation (Ki-67 staining) and increased apoptosis (cleaved 
caspase 3 staining). Scale bar: 100 µm. (E – H) Immunohistochemical quantification of p-
cMET, p-PDGFRß, Ki-67 and cleaved caspase 3. Data represent mean ± SEM (*P < 0.05; 
**P < 0.01; ***P < 0.001). 
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Figure 2.16: Foretinib reduces tumor growth in ONS76 medulloblastoma flank xenografts.  
(A and B) Effect of foretinib in ONS76 mouse flank xenografts treated with 60 and 100 
mg/kg by oral gavage, once every other day for 9 days (n = 6 in each group). Data represent 
group means ± SEM (*P < 0.05). (C) Differences in mean body weight between vehicle 
treated and foretinib (60 and 100 mg/kg) treated mice were not statistically significant by 1 
way ANOVA (P > 0.05) followed by Tukey’s Multiple Comparison Post-Test (P > 0.05 for 
all pairwise comparisons). Data represent group mean ± SEM. (D) ONS76 flank tumors 
treated with foretinib show potent inhibition of p-cMET, decreased cell proliferation (Ki-67 
staining) and increased apoptosis (cleaved caspase 3 staining). Scale bar: 100 µm. (E – G) 
Immunohistochemical quantification of p-cMET, Ki-67 and cleaved caspase 3. Data represent 
mean ± SEM (**P < 0.01; ***P < 0.001). 
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2.3.6 Characterization of Foretinib Pharmacokinetics and Brain 
Permeability  
To further evaluate the potential clinical relevance of foretinib in brain tumor 
treatment, we assessed the pharmacokinetics of the drug and its ability to penetrate into the 
brain. Nude mice were treated by oral gavage with 30, 60 and 100 mg/kg of foretinib, and 
blood and the perfused brains were harvested at specific time points (after 5 hours, 10 hours 
and 5 days of daily treatment). Foretinib was detected in samples from treated animals using 
high-performance liquid chromatography with tandem mass spectrometry (LC/MS/MS). 
Maximum concentrations of foretinib in the plasma and in the brain of mice occurred 5 hours 
after oral administration with no difference between dose levels (Figures 2.17A and 2.17B).  
 
Figure 2.17: Pharmacokinetics of foretinib in preclinical mouse models. 
Concentration-time profile of foretinib determined by high-performance liquid 
chromatography with tandem mass spectrometry (LC/MS/MS) method in the plasma (A) and 
in the brain (B) of mice, after oral administration of 30, 60 and 100 mg/kg of foretinib. Data 
represent mean of quadruplicates ± SEM. 
 
The same pharmacokinetic features in the plasma were previously reported in a phase 
I clinical trial of foretinib in adult patients with advanced solid tumors outside the central 
nervous system 183. This study established a dose of 3.6 mg/kg of oral foretinib as the 
maximum tolerated dose in human studies. The concentration of foretinib used in our mouse 
studies that better resembles the recommended dose in humans is 60 mg/kg since it has a 
human equivalent dose of 4.8 mg/kg197. Furthermore, after 5 consecutive days of treatment 
with 60 mg/kg of oral foretinib, the penetration of the drug in the brain was approximately 
14% (Table 2.1).    
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Table 2.1: Foretinib concentrations in mouse brain, mouse plasma and the brain/plasma ratio 
after administration of 30, 60 and 100 mg/kg by oral gavage 
Foretinib concentration Brain (ng/mL) Plasma (ng/mL) Ratio 
30 mg/kg (oral gavage)    
5 h 517 ± 20 3400 ± 345 0.152 
10 h 296 ± 85 2143 ± 670 0.138 
5 d 362 ± 38 3018 ± 328 0.120 
60 mg/kg (oral gavage)    
5 h 1270 ± 40 8600 ± 50 0.148 
10 h 804 ± 23 5540 ± 1110 0.145 
5 d 769 ± 67 5675 ± 475 0.135 
100 mg/kg (oral gavage)    
5 h 1810 ± 440 10700 ± 2350 0.169 
10 h 1483 ± 295 9667 ± 848 0.153 
5 d 1390 ± 280 11025 ± 1525 0.126 
NOTE: The results are the mean of measurements of 3 mice ± SEM. 
 
 
 We then assessed the distribution of foretinib in different mouse organs using matrix-
assisted laser desorption/ionization with time-of-flight mass spectrometer (MALDI-TOF) 
imaging. This technique allows direct imaging of compounds in tissue sections and uses mass 
spectrometry to confirm the presence of specific molecules. Foretinib produces a strong signal 
and the mass spectrum shows three well-defined peaks corresponding to the natural isotopic 
distribution of the drug (Figures 2.18A and 2.18B). Five hours after oral administration of 
foretinib, when it reaches the maximum plasma concentration, the drug is seen in the liver and 
also in the renal cortex (Figure 2.18C). The concentration of foretinib in the brain after oral 
gavage was below the threshold detection of MALDI-TOF imaging.   
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Figure 2.18: Distribution of foretinib in preclinical mouse models. 
 (A and B) Identification of foretinib by matrix-assisted laser desorption/ionization with time-
of-flight mass spectrometer (MALDI-TOF) imaging. m/z: mass-to-charge. (C) Distribution of 
foretinib in the liver and kidney of mice 5 hours after oral administration of 100 mg/kg. (D) 
Comparison of foretinib concentration (ng/mL) in different areas of the brain after intrathecal 
therapy (osmotic pumps) versus oral gavage. Data represent mean of triplicates ± SEM. (E) 
foretinib imaging with MALTI-TOF in the mouse brain after local delivery by osmotic pump. 
 
 
To explore the potential use of foretinib for intrathecal therapy in neuro-oncology we 
delivered the drug into the lateral ventricles of mice using osmotic pumps and assessed 
toxicity, drug quantification and distribution in the brain. In order to mimic human intrathecal 
chemotherapeutic regimens198, we delivered 6 mg/kg of foretinib for 28 days at a rate of 0.25 
µl/hour, which represents 10% of the oral dose of 60 mg/kg previously tested. Foretinib 
injected into the right lateral ventricle of mice was distributed through the cerebrospinal fluid 
to the supra- and infratentorial compartments. Interestingly, the concentration of foretinib in 
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the cerebellum after oral administration of 60 mg/kg for 5 consecutive days was similar to the 
concentration of the drug obtained by local delivery of a single dose of 6 mg/kg over a period 
of 26 days (Figure 2.18D). Foretinib was clearly detected by MALDI-TOF imaging in the 
right frontal lobe of mice due to its very high concentration at the drug delivery site (Figure 
2.18E). The drug was well tolerated and the mice did not display any signs of central nervous 
system toxicity.  
Collectively, these studies demonstrate for the first time, to our knowledge, that 
foretinib crosses the blood-brain barrier and can be safely administered as intrathecal therapy. 
 
 
 
2.3.7 Foretinib Reduces SHH Medulloblastoma Growth and 
Dissemination in Mouse Xenografts 
Having established that foretinib can effectively be delivered in the brain, we 
investigated its efficacy in mouse models of disseminated medulloblastoma. Daoy cells 
expressing luciferase were orthotopically implanted into the fourth ventricle of nude mice. 
Animals with a detectable signal by bioluminescence at 3 days post inoculation were treated 
by oral gavage either with vehicle (DMSO) or 60 mg/kg of foretinib once daily, 6 days a 
week, for 2 weeks. The weekly evaluation of tumor growth and dissemination by 
bioluminescence showed a significant reduction in tumor size and metastases in the animals 
treated with foretinib (Figures 2.19A and 2.19B), as confirmed by the smaller increase in the 
total photon flux from luciferase expressing Daoy xenografts (Figure 2.19C). Histological 
examination (H&E stain) of brains and spinal cords of animals in the control group showed a 
higher number of metastases in the ventricles and leptomeningeal spaces, as well as 
surrounding the spinal cord and the nerve roots, when compared to foretinib treated animals 
(Figures 2.19D and 2.19E). Since all animals developed hydrocephalus due to injection of 
tumor cells into the cerebrospinal fluid, we could not evaluate survival using this mouse 
model. 
These results demonstrate that foretinib is effective in reducing tumor growth and 
treating established medulloblastoma metastases in orthotopic mouse models of disseminated 
medulloblastoma.   
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Figure 2.19: Foretinib decreases tumor growth and metastases in intracranial xenografts 
models of medulloblastoma. 
Representative bioluminescence imaging of nude mice intraventricular xenografts treated 
with (A) vehicle control (10% DMSO, n = 11) or (B) foretinib (60 mg/kg, n = 11), orally once 
daily, 6 days a week, for 2 weeks. Foretinib decreases medulloblastoma growth as denoted by 
a smaller change in total photon flux (C) and the total number of metastases (D). Data 
represent group means ± SEM (**P < 0.01). (E) Representative H&E analysis of brain and 
spinal cord samples in the control group and the foretinib treated group. Arrows denote 
metastatic deposits in a representative animal from the control group while arrowheads denote 
metastases, smaller in number and size, of a representative animal from the foretinib treated 
group. Scale bar: 1000 µm.  
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2.3.8 Foretinib is Effective Against the Primary and the Metastatic 
Compartments in a Transgenic Model of Metastatic SHH 
Medulloblastoma  
To further validate our findings we tested the efficacy of foretinib in a recently 
published metastatic mouse model of SHH medulloblastoma175. The authors used the 
Sleeping Beauty (SB) transposon system where random insertion events through the genome 
lead to activation of oncogenes and disruption of tumor suppressor genes. Mobilizing the SB 
transposon in the cerebellar progenitor cells of Ptch+/- mice induced a very aggressive form 
of medulloblastoma with high incidence of leptomeningeal dissemination by 10 weeks of 
age175. We asked whether early and continuous treatment with foretinib could prevent the 
formation of metastases and improve survival in this mouse model. Osmotic pumps loaded 
with 6 mg/kg of foretinib or vehicle (10% cremophor) were implanted in 4 to 5 weeks old 
mice and delivered the drug for 28 days, at a rate of 0.25 µl/hour. Strikingly, foretinib treated 
animals showed a significant increase in survival (Figure 2.20A) and displayed 
medulloblastomas in the cerebellum with a less invasive phenotype when compared to 
controls (Figures 2.20B and 2.20C). Moreover, treatment with foretinib reduced the 
incidence of metastases by 36% (Figure 2.20D). Mice tolerated intrathecal administration of 
foretinib although 4 animals presented with intratumoral haemorrhage in the cerebellum (2 
animals in the vehicle control group and 2 animals in the foretinib treated group) most likely 
related to the tumor vasculature and not to the treatment with foretinib. 
Taken together, these results demonstrate that foretinib is effective both against the 
primary and the metastatic compartments in medulloblastoma, by reducing primary tumor 
invasion and preventing leptomeningeal dissemination in an aggressive mouse model of 
metastatic SHH medulloblastoma. 
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Figure 2.20: Foretinib prevents metastases formation and increases survival in a transgenic 
mouse model of metastatic SHH medulloblastoma.  
(A) Kaplan-Meier survival curves demonstrate that Ptch+/- mice with Sleeping Beauty 
transposition (Ptch+/-/SB11/T2Onc) have an increased survival after treatment with 6 mg/kg 
of foretinib by osmotic pump infusion (rate of 0.25 µl/hour for 28 days; n = 16) when 
compared to the vehicle control group (n = 18). The grey bar indicates the duration of 
treatment. (B and C) Primary medulloblastomas treated with foretinib display a less invasive 
phenotype as denoted by (B) the dashed line separating the tumor (T) and the normal (N) 
cerebellum in H&E sections, and by (C) the quantification of the percent tumor invasion (P < 
0.01). (D) Foretinib decreases the incidence of metastases in an aggressive model of 
metastatic medulloblastoma. Data represent group means ± SEM (P < 0.0001). 
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2.4 Discussion 
We show here that activation of cMET signaling is a hallmark feature of SHH 
medulloblastomas and correlates with poor outcome in pediatric patients. Targeting the cMET 
receptor with foretinib, an FDA approved kinase inhibitor that crosses the blood-brain barrier, 
significantly reduces primary medulloblastoma growth and invasion, diminishes the incidence 
of metastases and increases survival in disseminated mouse models of SHH medulloblastoma. 
Our study identifies for the first time a subgroup-specific targeted drug with promising 
efficacy against both medulloblastoma primary tumors and metastases. 
We demonstrate that cMET is highly expressed in SHH medulloblastomas although 
the mechanisms leading to cMET up-regulation in this subgroup remain unclear. A recent 
publication reported a high number of CNAs in SHH medulloblastomas 23 but the analysis of 
the same large cohort of samples (n=1,239) fail to show any focal gains or amplifications of 
cMET. Furthermore, of 332 medulloblastomas recently sequenced, there were no recurrent 
mutations or amplifications of the cMET gene192,199-201. These results suggest that the high 
expression of cMET is not driven by CNAs but may relate to the specific signaling events or 
cell of origin of the SHH subgroup. Interestingly, our previous finding that SPINT2, an 
inhibitor of cMET, is silenced by promoter methylation34 and the recent publication that 
cMET is among the most significantly hypermethylated genes in Group 4 tumors202, suggest 
that cMET regulation in medulloblastomas may be driven by epigenetic factors.  
Examination of molecular pathways characterizing SHH tumors with high and low 
cMET expression revealed distinct patterns of alteration. While low cMET SHH 
medulloblastomas were associated with deregulation of biological processes involved in 
neurogenesis and neurotransmission, high cMET SHH medulloblastomas were characterized 
by alterations in a number of cancer-related networks, namely cell migration, cell cycle, DNA 
repair and transcription. The activation of distinct biological pathways in high cMET SHH 
medulloblastomas supports the existence of a different cell of origin for these tumors, in 
keeping with a recent study that has shown that a specific population of Nestin-expressing 
neuronal progenitors in the cerebellum can give rise to SHH-driven medulloblastomas203. 
We identify a gene signature of cMET activators, including cMET and GAB1, unique 
to SHH-driven tumors. Our results are supported by a previous publication where 
immunoreactivity for GAB1 was reported to be a surrogate marker for SHH 
medulloblastomas25. Furthermore, we demonstrate that the cMET pathway activation status 
can segregate patients with SHH medulloblastomas into distinct prognostic outcomes. In 
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pediatric patients with SHH tumors, activation of cMET is correlated with an increased rate of 
relapse and a shorter progression-free survival. Notably, this association is not seen in adult 
SHH patients confirming the previously reported clinical and molecular distinction between 
adult and pediatric SHH medulloblastomas22. Furthermore, p-cMET status does not correlate 
with the presence of metastases or TP53 mutations, two known markers of poor prognosis 
across medulloblastoma subgroups204 and within the SHH subgroup205, respectively. We 
show that a simple immunohistochemical analysis of activated cMET provides a high quality 
clinical trial biomarker for identification of patients who could benefit from targeted therapy 
using cMET inhibitors. 
Foretinib, an FDA approved drug, had a dramatic therapeutic effect in SHH 
medulloblastoma, both in vitro and in vivo. Furthermore, our pharmacokinetic studies 
demonstrate for the first time that foretinib penetrates the blood-brain barrier and is well 
tolerated and distributed through intrathecal administration. As expected by the high affinity 
of foretinib to the cMET receptor, its overall antitumor effect is predominantly exerted 
through blockade of the cMET pathway although we have also shown that foretinib targets 
PDGFRß with lower affinity. Foretinib reduces primary medulloblastoma growth and 
invasion, and has also a potent activity against medulloblastoma metastases. Administration 
of foretinib to an aggressive metastatic mouse model of SHH medulloblastoma increases 
survival by 45% and diminishes the incidence of metastases by 36%. Interestingly, we show 
that foretinib also targets AKT, a downstream effector of both cMET and PDGFRß signaling, 
and recently identified as a key contributor to leptomeningeal dissemination in 
medulloblastoma175,176. Therefore, the anti-metastatic properties of foretinib may be related to 
its unique ability to target three key drivers in medulloblastoma dissemination, namely cMET, 
PDGFRß and PI3K. 
Given the high expression of cMET in SHH-driven medulloblastomas, the therapeutic 
regimen that may offer maximum benefit in this subset of patients is the combination of 
foretinib with an antagonist of SHH signaling. A significant antitumor effect was reported in a 
patient with metastatic medulloblastoma after inhibition of smoothened (SMO), a critical 
component of SHH pathway, although the response was transient due to the emergence of 
acquired resistance162. Thus, we anticipate that combining foretinib with a SMO inhibitor may 
have a synergistic and an anti-resistance effect treating cMET-dependent SHH 
medulloblastomas. 
In summary, we show that the FDA approved drug foretinib is effective treatment in 
preclinical murine models of metastatic SHH medulloblastoma. Given the dismal outcome 
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and lack of options for these patients, our results provide strong rationale for repurposing 
foretinib as a targeted agent in SHH-driven medulloblastoma.  
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Chapter 3  
The Connectivity Map Identifies Novel Small Molecules to 
Target Group 3 Medulloblastomav 
 
3.1 Introduction 
 As described previously, medulloblastoma consists of at least four distinct molecular 
subgroups: WNT, SHH, Group 3 and Group 413,16. These subgroups are characterized by 
divergent genetic aberrations, cytogenetic features, and distinct phenotypes including patient 
demographics and clinical outcome. Tumors with WNT pathway activation have the most 
favorable prognosis whereas Group 3 medulloblastomas have the worst outcome. Group 3 
tumors are restricted to pediatric patients, exhibit overexpression or amplification of MYC, 
and are frequently metastatic at the time of diagnosis18,20. These tumors are particularly 
resistant to conventional therapies with radiation and chemotherapy, even at maximal 
tolerated doses, highlighting the need for novel and more effective therapeutic options191,206. 
We used the Connectivity Map (C-MAP), a bioinformatic tool based on gene 
expression, to discover small molecules with high likelihood of efficacy against Group 3 
medulloblastomas. The C-MAP contains gene expression signatures of various cultured 
cancer cell lines treated with a library of small molecule compounds already approved by the 
Food and Drug Administration (FDA)207,208. This platform links drugs, genes and diseases by 
measuring similarity or dissimilarity in gene expression. Using a pattern-matching algorithm, 
the program is able to identify drugs predicted to revert the oncogenic gene signature of a 
given cancer to a nonmalignant or drug-sensitive gene expression profile. Previous studies 
have successfully used this approach to identify compounds with the ability to modulate 
various biological pathways or diseases209-212.  
In this study we identified subgroup-specific signatures with genes differentially 
expressed between each medulloblastoma subgroup and normal cerebellum. We then selected 
                                                
v
 The gene expression analysis in medulloblastoma samples and cell lines, and the C-MAP analysis were 
performed by Sameer Agnihotri and Stephen Mack. Assistance with cell viability assays using M441 and hf5281 
stem cells was obtained from Michelle Kushida, Renee Head and Xin Wang. Assistance with Western blot 
experiments using Group 3 medulloblastoma cell lines was obtained from Brian Golbourn, Samantha Olsen, 
Melissa Bryant and Mathiew Bebenek. The remainder of experiments described in this chapter were performed 
by the candidate. 
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the top up- and down-regulated genes to query the C-MAP database and obtain a list of 
compounds with likelihood to reverse the direction of gene expression in medulloblastoma. 
Piperlongumine (PL), a natural product isolated from the fruit of the Piper longum and 
previously known to have cytotoxic properties in cancer213, was the top candidate for non-
WNT tumors. Alsterpaullone (ALP), a CDK inhibitor, was identified as a potential 
therapeutic agent for Group 3 medulloblastomas. In subsequent validation experiments we 
sought to validate the predictions of the in silico drug screen. We showed that ALP is highly 
effective and selective in treating Group 3 medulloblastoma cell lines and mouse xenografts. 
Furthermore, ALP reverses Group 3 medulloblastomas gene signature and downregulates 
many cell cycle-related genes, including MYC. 
 
3.2 Materials and Methods 
 
3.2.1 Connectivity Map Analysis 
The subgroup-specific gene expression profiles of primary medulloblastomas were 
obtained from previously published datasets16. A list of genes differentially expressed 
between each medulloblastoma subgroup and normal cerebellum was obtained and the top 
200 up- and downregulated genes were selected to query the C-MAP database. Compounds 
with a negative enrichment score, which implies the ability to reverse the direction of 
expression of the gene signature of interest, and a p-value inferior to 0.05 were recorded as 
potential therapeutic agents for medulloblastoma207,208. 
 
3.2.2 Medulloblastoma Cell Lines 
The medulloblastoma cell lines (D425 and D458) were kindly provided by Dr. Annie 
Huang, Hospital for Sick Children, Toronto, Canada. D458-GFP/Luciferase cells were 
generated as described previously193. The primary medulloblastoma stem cell line (M441) and 
the fetal normal human brain stem cell line (hf5281) were generously provided by Dr. Peter 
Dirks, Hospital for Sick Children, Toronto, Canada. M441 cells were derived from a surgical 
specimen from a child with a Group 3 medulloblastoma of the cerebellum and obtained as 
previously described214,215. 
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3.2.3 Cell Proliferation Assays 
D425 and D458 cells were grown as suspension cultures and seeded in 96-well 
microplates at 10,000 cells per well. M441 and hf5281 were grown as adherent cultures and 
seeded in 96-well microplates at 4,000 and 5,000 cells per well, respectively. Cells were 
treated for 48h with different concentrations of PL (INDOFINE Chemical Company), ALP 
(A. G. Scientific), rottlerin (RTL; A. G. Scientific) and flunarizine (FZ; Sigma) or DMSO 
(control). Cell viability was determined by MTS and the absorbance measured at 490 nm 
(CellTiter 96 Aqueous One Solution Reagent; Promega). Three independent experiments 
were performed with 16 repeats per treatment condition. 
 
3.2.4 Medulloblastoma Mouse Xenografts 
All mouse studies were approved by the Institutional Animal Care and Use Committee 
of the University of Toronto and the Hospital for Sick Children, in Toronto, and performed in 
accordance to their policies and regulations. 
Medulloblastoma intracranial xenografts were established in 5-6 weeks old athymic 
nude mice (D425 and D458 cell lines) and in NOD scid gamma mice (M441 cell line) (both 
from Charles River Laboratories). Medulloblastoma cells (250,000 D425 and D458 cells; 
100,000 M441 cells) were implanted in the right cerebellum of mice. Six days after cell 
inoculation, animals were randomized into treatment cohorts, which included subcutaneous 
injections with vehicle control (10% DMSO), PL (50 mg/kg, daily for 2 weeks), ALP (30 
mg/kg, daily for 2 weeks), RTL (20 mg/kg, every other day for 2 weeks) or FZ (50 mg/Kg, 
daily for 2 weeks).  
In animals bearing D458-GFP/Luciferase xenografts, bioluminescence imaging was 
performed at 6 days after intracranial injection. Mice with a detectable signal were included in 
the study and tumor growth was monitored at one-week intervals using the IVIS Spectrum 
Optical In-vivo Imaging System (Caliper Life Sciences). 
Animals with signs of sickness or weight loss greater than 20% were euthanized and 
the brains harvested and fixed in 10% formalin. 
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3.2.5 Immunoblotting 
Cell lysates were prepared by adding RIPA buffer (Sigma) containing protease 
inhibitors (F. Hoffman-La Roche AG), 0.2 M sodium orthovanadate, 0.2 M sodium 
pyrophosphate and 0.2 M sodium fluoride. The Pierce BCA Protein Assay Kit (Thermo 
Scientific) was used to determine protein concentration. Proteins were separated on 7.5% or 
10% SDS-PAGE gels and transferred to PVDF membranes using a semidry transfer apparatus 
(Bio-Rad). The following antibodies were used: PARP (1:1,000; Cell Signaling), AKT 
(1:1,000; Cell Signaling), phospho-AKT (1:2,000; Ser473, Cell Signaling), α-tubulin 
(1:1,000; Cell Signaling), anti-mouse IgG conjugated to horseradish peroxidase (1:5,000; 
Amersham Biosciences) and anti-rabbit IgG conjugated to horseradish peroxidase (1:5,000; 
Cell Signaling). 
 
3.2.6 RNA Extraction and Gene Expression Analysis 
D425 and D458 medulloblastoma cells were treated with 5 µM of PL, 5 µM of ALP 
or DMSO (control) for 48h. RNA isolation was performed using the RNeasy Mini Kit 
(Qiagen) and gene expression data were generated using the Human PrimeView Arrays.  
GSEA was performed using gene sets from the NCI, GO, KEGG, PFAM and Biocarta 
pathway databases. Significant gene sets were identified (FDR < 0.05; P < 0.01) and 
visualized in Cytoscape and Enrichment Map software. 
A list of genes up- and down-regulated by ALP in D425 and D458 medulloblastoma 
cells was generated. The top 200 genes were selected to query the C-MAP database and to 
determine if ALP and PL were able to reverse the gene expression profile of Group 3 
medulloblastoma cells (P < 0.05). 
 
3.2.7 Statistical Analysis 
The Kaplan-Meier estimate and a log-rank test were used to generate survival curves. 
Experiments were performed in triplicate and results were expressed as mean ± SEM. 
Statistical analysis was performed using GraphPad Prism 5 Software. A P-value inferior to 
0.05 was considered as significant.  
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3.3 Results 
 
3.3.1 The C-MAP Identifies Novel Candidate Drugs to Treat 
Medulloblastoma 
To identify novel drugs with potential antitumor effect in medulloblastoma we queried 
the C-MAP database using the previously published gene expression signatures of the four 
molecular subgroups of medulloblastoma16. The top 20 drugs that were able to reverse the 
gene expression profile of each medulloblastoma subgroup are listed in Table 3.1. 
Piperlongumine, a natural product derived from the plant species Piper longum, was the 
compound with the highest negative enrichment score for non-WNT medulloblastomas. The 
compounds identified as potential novel therapies for WNT medulloblastomas are distinct 
from the ones identified for non-WNT tumors. On the other hand, the drugs listed for Group 3 
and Group 4 tumors are very similar.   
 We then asked which compounds were specific for Group 3 medulloblastomas. On top 
of the list, a CDK inhibitor (alsterpaullone), a protein kinase C (PKC) inhibitor (rottlerin) and 
two calcium channel inhibitors (denatonium benzoate and flunarizine) showed significant 
negative enrichment (Table 3.2). 
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Table 3.1: Top 15 drugs specific for Group 3 medulloblastomas, as predicted by the 
Connectivity Map analysis (P<0.05). 
     
    NOTE: The compounds were ranked based on negative enrichment score. 
    CDK, cyclin-dependent kinase; PKC, protein kinase C 
 
 
 
Rank C-MAP name Enrichment Drug category 
96 alsterpaullone -0.765 CDK inhibitor 
130 rottlerin -0.725 PKC inhibitor 
69 denatonium benzoate -0.701 calcium channel inhibitor 
104 flunarizine -0.664 calcium channel inhibitor 
107 bupropion -0.661 dopamine receptor antagonist 
117 pyridoxine -0.651 pyridoxal kinase agonist 
31 flunisolide -0.644 phospholipase A2 inhibitor 
125 etamsylate -0.643 prostaglandin inhibitor 
135 prenylamine -0.635 calcium channel inhibitor 
139 practolol -0.631 beta-adrenergic antagonist 
140 betaxolol -0.629 beta-adrenergic antagonist 
144 propylthiouracil -0.626 thyroid peroxidase inhibitor 
136 lorglumide -0.57 colecystokinin antagonist 
138 amiodarone -0.569 calcium channel inhibitor 
113 PNU-0251126 -0.549 not assessed 
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3.3.2 C-MAP Candidate Drugs Piperlongumine, Alsterpaullone, 
Rottlerin and Flunarizine Reduce Proliferation of Group 3 
Medulloblastoma Cell Lines 
To validate the results of our C-MAP analysis we selected piperlongumine (the best 
candidate for non-WNT medulloblastomas) and the top three drugs predicted to be specific 
for Group 3 medulloblastomas (alsterpaullone, rottlerin and flunarizine). Denatonium 
benzoate is known to be the bitterest compound and was excluded from our study. 
We examined the effects of each drug on the proliferation of three Group 3 
medulloblastoma cell lines (the established cell lines D425 and D458, and the primary 
medulloblastoma stem cell line M441) and a fetal neural stem cell line (hf5281). 
Piperlongumine (PL) and rottlerin (RTL) treatment for 48 hours markedly reduced cell 
proliferation in medulloblastoma cells at 5 µM (Figures 3.1A and 3.1B) whereas 
alsterpaullone (ALP) treatment showed the same efficacy at 1 µM (Figure 3.1C). Treatment 
with flunarizine (FZ) decreased cell proliferation at higher concentrations (50 and 100 µM) 
(Figure 3.1D).  
Interestingly, the most sensitive cell line to the Group 3 medulloblastoma candidate 
drugs was the primary stem cell line derived from a patient with a Group 3 medulloblastoma 
of the cerebellum (M441). When primary normal cells (hf5281) were incubated with PL, ALP 
and RTL there was little reduction in cell proliferation, even at the highest concentration 
tested of 10 µM, thus indicating that these compounds may have selective killing properties to 
medulloblastoma tumor cells. 
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Figure 3.1: Cytotoxic effect of piperlongumine, alsterpaullone, rottlerin and flunarizine in 
Group 3 medulloblastoma cell lines. 
Established medulloblastoma cell lines (D425 and D458), a primary medulloblastoma stem 
cell line (M441) and a fetal neural stem cell line (hf5281) were treated with various 
concentrations of (A) piperlongumine, (B) rottlerin, (C) alsterpaullone and (D) flunarizine for 
48 hours. Cell viability was measured by MTS assay. Data represent mean of triplicates ± 
SEM. 
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3.3.3 In Vivo Antitumor Effect of Piperlongumine, Alsterpaullone and 
Rottlerin in Group 3 Medulloblastomas 
We next investigated the efficacy of PL, ALP, RTL and FZ in established 
medulloblastoma xenografts representative of Group 3 medulloblastomas. D458 cells 
expressing luciferase were implanted in the right cerebellum of nude mice and 
bioluminescence imaging was performed at 6 days post inoculation. Animals with a 
detectable signal were treated by subcutaneous injection with PL (50 mg/kg, daily for 2 
weeks), ALP (30 mg/kg, daily for 2 weeks), RTL (20 mg/kg, every other day for 2 weeks), 
FZ (50 mg/Kg, daily for 2 weeks) or vehicle control (10% DMSO). Marked reduction in 
medulloblastoma growth was observed in mice treated with PL, ALP and RTL when 
compared to DMSO-treated controls, as confirmed by bioluminescence imaging (Figures 
3.2A and 3.2B) and by histological examination (H&E stain) of the brains (Figure 3.3). A 
significant increase in survival was also seen in mice treated with PL (Figure 3.4A; P = 
0.0011), ALP (Figure 3.4B; P = 0.0043) and RTL (Figure 3.4C; P = 0.0262). As expected by 
the in vitro effects of FZ in cell proliferation, only seen at very high concentrations, this drug 
was not able to prolong survival of mice bearing medulloblastoma xenografts (Figure 3.4D). 
We then tested the two most promising drugs, PL and ALP, in nude mice with D425 
cerebellar xenografts and showed that both drugs significantly increase survival (Figures 
3.5A and 3.5B; P < 0.05) and reduce medulloblastoma growth (Figure 3.5C). 
Collectively, these results confirm that the C-MAP top predicted drugs for Group 3 
medulloblastomas are effective in treating orthotopic mouse models of the disease. 
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Figure 3.2: Piperlongumine, alsterpaullone, and rottlerin, reduce tumor growth in D458 
medulloblastoma xenografts.  
(A) Representative bioluminescence imaging of D458 cerebellar xenografts treated with 
vehicle control (10% DMSO, n = 14), piperlongumine (50 mg/kg, s.c., daily for 2 weeks; n = 
10), alsterpaullone (30 mg/kg, s.c., daily for 2 weeks; n = 14) and rottlerin (20 mg/kg, s.c., 
every other day for 2 weeks; n = 11). (B) Connectivity Map predicted drugs reduce 
medulloblastoma growth as denoted by a smaller change in total photon flux. Data represent 
group means ± SEM. 
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Figure 3.3: Representative H&E staining of D458 medulloblastomas treated with 
piperlongumine, alsterpaullone and rottlerin. 
Representative H&E staining demonstrates that mice bearing D458 tumors treated with 
piperlongumine, alsterpaullone and rottlerin have smaller medulloblastomas in the 
cerebellum. Scale bar: 500 µm. 
Figure 3.4: Survival of D458 intracranial xenografts treated with piperlongumine, 
alsterpaullone, rottlerin and flunarizine. 
 (A – D) Kaplan-Meier survival curves demonstrate that mice harboring orthotopic D458 
medulloblastoma xenografts have an increased survival after treatment with piperlongumine 
(PL; P = 0.0011), alsterpaullone (ALP; P = 0.0043) and rottlerin (RTL; P = 0.0262). Survival 
differences were calculated using a log-rank test. 
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Figure 3.5: Piperlongumine and alsterpaullone increase survival of D425 medulloblastoma 
xenografts. 
Kaplan-Meier estimate displays survival of nude mice with D425 cerebellar xenografts 
treated with (A) piperlongumine (PL) or (B) alsterpaullone (ALP). Survival differences were 
calculated using a log-rank test. (C) Representative H&E staining demonstrates reduction in 
medulloblastoma growth after treatment with PL and ALP, when compared to the control 
group. Scale bar: 500 µm. 
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3.3.4 Alsterpaullone Shows In Vitro and In Vivo Specificity for Group 3 
Primary Medulloblastoma Stem Cells  
To determine the mechanisms by which PL and ALP exert their antitumor effect, we 
treated D425, D458 and M441 medulloblastoma cells with both drugs for 48h and assessed 
apoptosis and AKT pathway inhibition. Western blot analysis showed that ALP induced 
apoptosis (Figure 3.6A) and potently inhibited AKT pathway activation (Figure 3.6B) at 
lower concentrations than PL.  
 
Figure 3.6: Piperlongumine and alsterpaullone induce apoptosis and inhibit AKT pathway 
activation. 
Representative Western blots demonstrating (A) induction of apoptosis and (B) AKT pathway 
inhibition after piperlongumine (PL) and alsterpaullone (ALP) treatment for 48h in D458 and 
D425 medulloblastoma cells.  
 
Interestingly, the patient derived medulloblastoma stem cell line was particularly 
sensitive to the in vitro effect of the Group 3 specific drug, ALP (Figures 3.7A – 3.7C). 
Furthermore, M441 cerebellar xenografts treated with PL did not show a survival advantage 
when compared to the control group (Figure 3.8A) whereas treatment with ALP significantly 
increased survival and decreased medulloblastoma tumor growth (Figures 3.8B and 3.8C). 
A
B
D458
Co
nt
ro
l
1 µM 5 µM
PL
PARP
Cleaved PARP
њWXEXOLQ
Co
nt
ro
l
1 µM 5 µM
ALP
D425
Co
nt
ro
l
1 µM 5 µM
PL
Co
nt
ro
l
1 µM 5 µM
ALP
D458
Co
nt
ro
l
1 µM 5 µM
PL
S$.7
$.7
Co
nt
ro
l
1 µM 5 µM
ALP
њWXEXOLQ
D425
Co
nt
ro
l
1 µM 5 µM
PL
Co
nt
ro
l
1 µM 5 µM
ALP
Chapter 3 – C-MAP Identifies Novel Small Molecules to Target Group 3 Medulloblastoma 
 117 
These results validate the subgroup specific C-MAP predictions and identify ALP as an 
effective therapy for Group 3 medulloblastoma. 
 
Figure 3.7: In vitro efficacy of alsterpaullone targeting medulloblastoma stem cells derived 
from a patient with a Group 3 medulloblastoma.  
(A) Primary medulloblastoma stem cells (M441) are more sensitive to the cytotoxic effects of 
alsterpaullone (ALP) than of piperlongumine (PL). Scale bar: 50 µm. (B) Representative 
Western blots demonstrate induction of apoptosis in M441 cells after PL treatment (at 5 µM) 
and ALP treatment (at 1 µM). (C) ALP potently inhibits AKT pathway activation in Group 3 
derived medulloblastoma stem cells. 
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Figure 3.8: In vivo efficacy of alsterpaullone treating mice with primary cerebellar 
xenografts.  
(A and B) Kaplan-Meier survival curves demonstrate the subgroup-specific efficacy of 
alsterpaullone (ALP) increasing survival of mice with M441 cerebellar xenografts. Survival 
differences were calculated using a log-rank test. (C) Representative H&E staining of mouse 
cerebellar xenografts in the control group, the piperlongumine (PL) treated group and the 
ALP treated group. Scale bar: 500 µm. 
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3.3.5 Alsterpaullone Inhibits MYC and other Cell Cycle Related 
Genes 
To identify downstream transcriptional events induced by ALP, we performed the 
genomic profiling of Group 3 medulloblastoma cell lines (D425 and D458), after treatment 
for 48 hours. When compared to DMSO treated medulloblastoma cells, ALP treated cells 
showed down-regulation of genes involved in cell cycle, including MYC (Figure 3.9A). 
GSEA was performed with gene sets compiled from the NCI, GO, KEGG, PFAM and 
Biocarta pathway databases. To visualize significant gene sets (FDR < 0.05; P < 0.01) as 
interaction networks Cytoscape and Enrichment Map were used. The top-scoring gene sets 
down-regulated by ALP were mainly cell cycle-related transcriptional signatures (Figures 
3.9B and 3.9C). In addition, ALP also inhibits several cancer-related networks (namely 
mTOR signaling, PTEN signaling, RAS signaling, Aurora kinase signaling, insulin signaling) 
and other biological processes including RNA processing, transport and splicing, DNA repair, 
chromatin organization and histone modifications, carbon metabolism and phosphatase 
activity (Figure 3.10). Gene sets up-regulated by ALP involve the inflammatory response 
(TNF signaling, MHC antigen presentation) and tissue regeneration (wound response and 
coagulation cascade, tissue morphogenesis, muscle contraction), as well as olfactory 
signaling, STAT signaling, alkene metabolism, lipid transport and neuropeptide receptor 
activity (Figure 3.10). 
Interestingly, when we queried the C-MAP database using the gene expression 
profiling of D425 and D458 medulloblastoma cells after treatment with ALP and PL, we 
found that only ALP was able to significantly reverse gene expression as determined by the 
high positive enrichment score (0.995) and low p-value (P < 0.000001) (Figures 3.11 and 
3.12). 
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Figure 3.9: Genomic profiling of Group 3 medulloblastoma cell lines treated with 
alsterpaullone demonstrates down-regulation of cell cycle related genes, including MYC.  
(A) Heatmap illustrating the genes up and down-regulated following treatment with 
alsterpaullone (ALP) in two Group 3 medulloblastoma cell lines. MYC and other genes 
involved in cell cycle are down-regulated by ALP. (B) Table of the top 10 gene sets up-
regulated or down-regulated by ALP. (C) Enrichment plots showing inhibition of cell cycle 
related gene sets. 
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Figure 3. 10: Biological pathways and processes up- and down-regulated by alsterpaullone. 
Gene Set Enrichment Analysis (GSEA) comparing gene sets up- and down-regulated by 
alsterpaullone (ALP) in D458 and D425 medulloblastoma cells (FDR < 0.05; P< 0.01). 
Cytoscape and Enrichment Map were used for visualization of the GSEA results. The 
enriched gene sets were grouped by their similarity, represented as nodes, and mapped as a 
network. The size of each node determines the total number of genes within each gene set.  
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Figure 3.11: Alsterpaullone reverses Group 3 medulloblastoma gene expression signature. 
Alsterpaullone is highly ranked as a compound with the ability to reverse the gene expression 
profile of Group 3 medulloblastoma cell lines as shown by (a) the C-MAP analysis and (b) 
the Significance Analysis of Microarrays (SAM) plot. 
 
 
 
A
B
cmap name mean n enrichment p-value VSHFLÀFLW\ % non-null
alsterpaullone 0.853 3 0.995 < 0.000001 0.0116 100
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Figure 3.12: The gene expression profile of Group 3 medulloblastomas is not affected by 
piperlongumine.  
(A and B) The gene expression profile of Group 3 medulloblastoma cell lines is not affected 
by piperlongumine treatment as determined by (a) the C-MAP analysis and (b) the 
Significance Analysis of Microarrays (SAM) plot. 
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3.4 Discussion 
We have used an in silico gene expression-based screening for drug discovery in 
medulloblastoma. Our approach, called the Connectivity Map (C-MAP), identified the CDK 
inhibitor ALP as a compound with the ability to reverse the gene expression signature of 
Group 3 medulloblastomas and, therefore, with potential specific antitumor effect. We 
validated the C-MAP hypothesis by demonstrating the efficacy of ALP both in in vitro and in 
vivo models of Group 3 medulloblastoma. Our study provides evidence for the use of 
chemical genomics to identify modulators of biological processes that drive the 
medulloblastoma subgroups. 
The C-MAP analysis, using the gene expression signatures of the four molecular 
subgroups of medulloblastoma, led to interesting observations. The drugs predicted for the 
WNT subgroup were distinct from the other subgroups. Strikingly, methylprednisolone (a 
steroid known to have a beneficial effect in brain tumors) and four chemotherapeutic agents 
currently in use for medulloblastoma treatment (etoposide, methotrexate, semustine and 
lomustine) were only listed in the WNT subgroup, which has the best response to treatment 
and the best outcome. On the other hand, PL was the top ranked compound for non-WNT 
medulloblastomas suggesting the ability of this compound to reverse common biological 
processes in these tumors. The predictions for Group 3 and Group 4 medulloblastomas 
included several shared compounds, in agreement with the genetic similarity between the two 
subgroups. Doxorubicin, a well-known chemotherapeutic agent but not used to treat 
medulloblastoma, was identified has a drug with potential efficacy for both Group 3 and 
Group 4 tumors.  
The top ranked compound with predicted specificity for Group 3 medulloblastoma 
was ALP, a potent inhibitor of CDK1/cyclin B and CDK 5. The cell-cycle kinases play an 
important role in normal development and their deregulation is associated with aberrant 
division and uncontrolled proliferation in various cancers216,217. In cerebellar development, 
cyclins D1 and D2 play a crucial role in the postnatal expansion of the granule neuron 
precursors in the EGL. As these cells exit the cell cycle and begin to differentiate, they 
migrate inwards through the Purkinje cell layer to form the IGL of the adult cerebellum6,218. 
The SHH pathway regulates the GNPs proliferation inducing the expression of the 
transcription factor GLI1, which up-regulates the expression of cyclin D1 and cyclin D2, via 
N-MYC219,220. Removal of both cyclins D1 and D2 in animal models results in severe 
cerebellar hypoplasia due to decreased proliferation and increased apoptosis of GNPs221. In 
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Ptch+/- mice, known to develop spontaneous cerebellar medulloblastomas, loss of cyclin D1 
(Ptch+/-;Ccnd1-/-) significantly reduces the incidence of tumors222. On the other hand, loss of 
CDK inhibitors, Ink4c or Ink4d, triggers medulloblastoma formation in p53-null mice223. A 
recent study has shown that CDK5 is also required for the normal development of the 
cerebellum. Cdk5 conditional knockout mice display a smaller cerebellum and a profound 
disturbance in migration of granule cells224.  
Members of the Cyclin/CDK complex are frequently amplified or up-regulated in 
human medulloblastoma. Li et al. described amplifications of the CDK4, CDK6, CCND1 (or 
cyclin D1) and CCND2 (or cyclin D2) genes in primary medulloblastomas225, raising the 
possibility of using CDK inhibition to suppress medulloblastoma formation. Interestingly, it 
has been shown in mouse models of lymphoma and hepatoblastoma that MYC sensitizes 
tumor cells to undergo apoptosis in response to CDK1 inhibition, through a mechanism 
independent of p53 status226. Due to the limited success in developing small molecule 
inhibitors of MYC, targeting important cellular processes, such as the cell cycle, may prove to 
be a suitable therapeutic strategy in MYC-dependent tumors, including Group 3 
medulloblastomas.  
Previous studies have shown the antitumor effects of ALP through induction of 
apoptosis in breast cancer and leukemia cells227-229. We report for the first time the cytotoxic 
effects of ALP in medulloblastoma. ALP effectively decreased cell proliferation and induced 
apoptosis through AKT pathway blockade. In mouse xenografts of Group 3 medulloblastoma, 
treatment with ALP significantly reduced tumor growth and improved survival. As for the 
other top candidate for non-WNT tumors, PL, it showed in vitro efficacy for higher drug 
concentrations than ALP and it failed to improve survival of primary medulloblastoma 
xenografts. These experimental results confirm the C-MAP hypothesis pointing ALP as a 
Group 3-specific drug. In fact, we demonstrate that ALP down-regulates several cell cycle 
related genes, including MYC, and, unlike PL, treatment with ALP reverses the gene 
expression profile of Group 3 medulloblastoma cell lines. Our chemical genomics study 
provides strong rationale for advancing alsterpaullone as a targeted therapy in Group 3 
medulloblastoma. 
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Chapter 4  
Concluding Remarks and Future Directions 
 
For a neurosurgeon, the complete resection of a brain tumor is an extremely rewarding 
experience and we tend to believe that such a successful operation will cure the patient. That 
is true for many cases but not all, particularly the malignant neoplasms. This simultaneously 
intriguing and disappointing observation highlights the need to better understand the biology 
of brain tumors for improving patient management. 
 I have decided to study medulloblastoma, the commonest malignant pediatric brain 
tumor, and a cause of severe neurological disabilities in children, secondary to therapy. An 
ever-increasing amount of genomic data on medulloblastoma is being generated in 
laboratories around the world using high-throughput technologies. Converting the data 
contained in the gene signatures of medulloblastoma into therapeutic approaches remains 
challenging but it is critically needed to improve the survival and quality of life of children 
with medulloblastoma. 
The main goal of my research project was to use genomic data for drug discovery in 
medulloblastoma. I started with a simple approach using a therapeutic target known to be 
relevant in medulloblastoma. Our studies identified cMET as a hallmark of SHH 
medulloblastomas and demonstrated a significant correlation of high cMET expression with 
increased tumor relapse and poor survival. Therefore, cMET can be used as a clinical 
biomarker to identify patients who may benefit from anti-cMET therapies. Foretinib, an FDA 
approved inhibitor of cMET with the ability to cross the blood-brain barrier, was highly 
effective in preclinical models of SHH medulloblastoma. Strikingly, foretinib reduced the 
number of metastasis and increased survival in an aggressive transgenic mouse model of 
metastatic SHH medulloblastoma.    
The results from this study provide strong evidence to advance foretinib into clinical 
trials for SHH medulloblastomas. However, there are interesting questions to be followed in 
the future. First, the mechanisms of cMET up-regulation remain unclear, since the genomic 
analysis performed in large cohorts of medulloblastoma samples failed to demonstrate 
recurrent mutations or amplifications of the cMET gene. Previous findings that the cMET 
inhibitor, SPINT2, is silenced by promoter methylation in primary medulloblastomas suggest 
a role for epigenetics in cMET regulation. Second, the high expression of cMET in SHH-
Using Genomics for Drug Discovery in Medulloblastoma 
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driven medulloblastomas raises the important question whether a combined therapy with 
foretinib and a SMO inhibitor would offer a survival benefit and overcome drug resistance.  
  
 Group 3 medulloblastomas are MYC-driven tumors associated with a very poor 
prognosis. Since MYC direct targeting hasn’t been successfully achieved, an alternative 
approach is to identify compounds that inhibit important cellular processes. We have used the 
C-MAP, a gene expression-based computational drug screen, to identify small molecules with 
predicted ability to reverse the gene expression signature of Group 3 medulloblastomas. Our 
study identified 15 compounds with high likelihood of efficacy against this subgroup of 
medulloblastoma. The top-ranked drug was ALP, a CDK inhibitor. Subsequent validation of 
these findings confirmed that ALP is highly effective and specific both in in vitro and in vivo 
models of Group 3 medulloblastomas. Interestingly, the chemical genomic profiling of ALP 
confirms inhibition of MYC-associated transcriptional activity and reveals enrichment of cell 
cycle signatures.  
 The clinical aggressiveness of Group 3 medulloblastomas anticipates that the design of 
novel therapeutic regimens will need to include a combination of drugs. An open question 
from our study is whether ALP, as a cell cycle modulator, could sensitize medulloblastoma 
cells to standard chemotherapy and radiation. The combination of ALP with chromatin 
modifiers such as the histone deacetylase inhibitors (HDAC), represents another important 
therapeutic avenue for future studies, since the deregulation of chromatin-associated genes 
has been recently identified in Group 3 medulloblastomas192,199-201,230.  
 
 In summary, the results from my research led to the following original conclusions, 
which can be immediately translated into the clinic: 
1. cMET is a molecular biomarker of the SHH subgroup of medulloblastomas and can 
identify a subset of patients who may benefit from cMET targeted therapies. cMET 
and p-cMET can be easily detected by immunohistochemistry in any pathology lab. 
2. Foretinib is a potent cMET inhibitor, FDA approved, that crosses the blood-brain 
barrier. Our preclinical studies indicate that this drug is a good candidate to be 
included in clinical trials as targeted therapy in SHH medulloblastoma. 
3. We describe a methodology using mass spectrometry to sistematically identify and 
quantify small molecule inhibitors in the central nervous system, a key approach in 
neuro-oncology. 
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4. The preclinical studies with Alsterpaullone indicate this drug is a good candidate for 
Group 3 medulloblastomas and suggest it can be readily advanced into clinical trials, 
either alone or in combination with conventional therapies. 
 
 ***  
 
 I will conclude with some brief more personal remarks. 
The three years spent in Toronto set the stage for a greater challenge: to create a Brain 
Tumor Research Centre in Portugal. The first steps were successfully taken with the 
establishment of a Brain Tumor Bank at the Biobank of Instituto de Medicina Molecular 
(Biobanco-IMM). In just over two years we have collected more than 300 brain tumor 
samples with matched blood, plasma and detailed clinical information. While most samples 
come from patients treated at the Department of Neurosurgery at Hospital de Santa Maria, we 
have gradually been collecting samples from other hospitals in Lisbon and across the country. 
We can proudly say that we have the largest clinically annotated collection of brain tumors in 
Portugal comprising over 1,000 biological samples. Furthermore, we have implemented at 
Biobanco-IMM the primary stem cell culture of brain tumors and metastasis. My vision for 
this project is to foster brain tumor research and to be part of major discoveries in the field 
through teamwork and collaboration. In keeping with this goal I have already established 
national and international collaborations, such as the participation in the medulloblastoma 
international consortium, MAGIC. Recently, an award from Fundação Millennium bcp 
allowed the project to spread its wings promoting both neurosurgical care and brain tumor 
research to help children in Africa, namely in Portuguese speaking countries like Angola and 
Mozambique. Through a cooperation protocol between IMM, Hospital de Santa Maria and 
the Ministry of Health of those African countries, we aim to provide education and surgical 
training to local neurosurgeons and to help them establishing a brain tumor bank.   
I am looking forward for the busy and exciting years ahead. 
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